Likelike的个人主页 - 老虎社区

Likelike

Likelike

Like like

IP属地：未知

93关注

29粉丝

0主题

0勋章

2021-12-11

calm before the tsunami...i wish...like like

Sea Ltd stock dropped more than 5% in morning trading

2021-11-30

Apple rise a day keep the shorters away...i wish..like like

Apple Stock: What to Expect During the Holiday Season

2021-11-17

Hope the new CFO can create breaking amazing accounting...i wish.. like like

抱歉，原内容已删除

2021-11-13

Pfizer the old giant ,time to wake upupup...i wish...like like

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.

2021-11-08

nio pls niu niu(bull bull)...like like

NIO share price on watch ahead of Q3 earnings

2021-11-04

very detailed and well thought analysis,superb thanks...like like...

Ocugen: WHO Approval For Covaxin Is Potentially A Red Herring For Investors

2021-11-01

Just a thinker, will the masses need credit card like Mastercard Visa Amex when anyone can BNPL on those online shops? .... like like

3 Warren Buffett Stocks to Buy in November

2021-11-01

$Ford(F)$csuch an old time car company yet stock price is just a fraction of Tesla's, Ford need to employ dreamers management but still give dividends hor..i wish ...like like...

2021-10-20

nio niu (bullish) yah... like like

NIO May Bring ET7's Electric Drive System To All Models: Report

2021-10-18

very good effort writeup, but layman like me best wish is yoursuggestion what price buy ,what price sell,no obligation jus indication haha thanks,like like....

抱歉，原内容已删除

2021-10-18

marketing power to the moon......like like

抱歉，原内容已删除

2021-10-18

$20 by New Year Day...i wish.. like like

Ford To Invest $316M On UK EV Plant

2021-10-17

sea tsunami up up up ....like like

5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025

2021-10-12

up up like like

Ocugen stock surged another 11% in premarket trading

2021-10-08

will this become another CEI,i wish...like like

Sundial Growers gained nearly 17% in premarket trading

2021-09-30

sometimes all tis old cos. really must learn from Elon Musk: talk big and do fast than whine sorrow and do slow...jus a small thinker ....like like

抱歉，原内容已删除

2021-09-30

Nio to the multiverse moons yeah...

抱歉，原内容已删除

2021-09-29

EVery EV Evolute EVeryone EVentually.[财迷]

Some hot EV stocks rallied in morning trading

2021-09-28

reaching $15 aiming $16

@Zonnnggg:$Ford(F)$More?

2021-09-23

Nio niu (bull)ah!

Nio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4091708143350050","uuid":"4091708143350050","gmtCreate":1628605862019,"gmtModify":1632926032280,"name":"Likelike","pinyin":"likelike","introduction":"","introductionEn":null,"signature":"Like like","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":29,"headSize":93,"tweetSize":42,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.58%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.24","exceedPercentage":"60.05%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":605437594,"gmtCreate":1639212100832,"gmtModify":1639212101161,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"calm before the tsunami...i wish...like like","listText":"calm before the tsunami...i wish...like like","text":"calm before the tsunami...i wish...like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605437594","repostId":"1133027099","repostType":4,"repost":{"id":"1133027099","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639152670,"share":"https://ttm.financial/m/news/1133027099?lang=&edition=full","pubTime":"2021-12-11 00:11","market":"us","language":"en","title":"Sea Ltd stock dropped more than 5% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133027099","media":"Tiger Newspress","summary":"Sea Ltd stock dropped more than 5% in morning trading.","content":"<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Ltd stock dropped more than 5% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Ltd stock dropped more than 5% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-11 00:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133027099","content_text":"Sea Ltd stock dropped more than 5% in morning trading.","news_type":1,"symbols_score_info":{"SE":0.9}},"isVote":1,"tweetType":1,"viewCount":2012,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609255210,"gmtCreate":1638287916044,"gmtModify":1638287916186,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Apple rise a day keep the shorters away...i wish..like like","listText":"Apple rise a day keep the shorters away...i wish..like like","text":"Apple rise a day keep the shorters away...i wish..like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609255210","repostId":"1158390889","repostType":4,"repost":{"id":"1158390889","kind":"news","pubTimestamp":1638285505,"share":"https://ttm.financial/m/news/1158390889?lang=&edition=full","pubTime":"2021-11-30 23:18","market":"us","language":"en","title":"Apple Stock: What to Expect During the Holiday Season","url":"https://stock-news.laohu8.com/highlight/detail?id=1158390889","media":"TheStreet","summary":"The 2021 holiday shopping season has officially started. Here is what Apple investors should expect of the Cupertino company and its stock in the next few weeks.Black Friday and Cyber Monday are behind us. With that, the 2021 holiday season in the US and parts of the world has officially begun. Consumer product and service companies like Apple are staring into the busiest weeks of sales in the year.Figure 1: Apple's iPhone, Apple Watch and Air Pods boxes.Today, the Apple Maven talks about what A","content":"<p>The 2021 holiday shopping season has officially started. Here is what Apple investors should expect of the Cupertino company and its stock in the next few weeks.</p>\n<p>Black Friday and Cyber Monday are behind us. With that, the 2021 holiday season in the US and parts of the world has officially begun. Consumer product and service companies like Apple are staring into the busiest weeks of sales in the year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/84c9d46c1a03b350ba81dcd1e6e39c83\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple's iPhone, Apple Watch and Air Pods boxes.</span></p>\n<p>Today, the Apple Maven talks about what Apple stock&nbsp;investors should think about as the shopping season kicks into gear.</p>\n<p><b>Apple to benefit from strong consumer</b></p>\n<p>At the highest level possible, Apple is likely to benefit from a rising tide that lifts all boats in 2021. The chart below clearly shows that consumer spending in the US has not only recovered from the 2020 flash recession, but it has been “making up for lost time”. Spending trends have even accelerated slightly compared to the pre-pandemic period.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/edfb88f466fa1cfe1c35bddbd1cf1bb7\" tg-width=\"756\" tg-height=\"357\" width=\"100%\" height=\"auto\"><span>Figure 2: Consumer spending in US.</span></p>\n<p>Regarding the holiday period, however, consumer product and service sales may look a bit atypical. Adobe has recently&nbsp;reported&nbsp;that Black Friday activity online dropped year-over-year for the first time ever. Online sales reached $8.9 billion, lower than 2020’s $9 billion.</p>\n<p>Without context, these numbers may look concerning. But once again, there is nothing typical about this COVID-19 crisis. Black Friday likely suffered from (1) consumers buying earlier than usual, to avoid delayed deliveries in late November and December, and (2) supply chain constraints causing shortages and missed sales opportunities.</p>\n<p><b>Apple could do better than average</b></p>\n<p>The demand scenario described above is at least modestly optimistic, in my view, even if not without challenges on the supply side. Even so, I think that Apple has a good chance of performing better than average in the next few weeks.</p>\n<p>For starters, the Cupertino company is&nbsp;one of the best in the world at managing inventory&nbsp;and supply chain. Consider, however, that CEO Tim Cook&nbsp;has already warned of an impact&nbsp;of $6 billion to revenues in the holiday quarter caused by the production and logistics bottlenecks.</p>\n<p>Second, the demand for Apple’s products and services seems unshaken.I have discussed a few times that the iPhone, for example, is likely to have its best years of sales ever in fiscal 2021 and 2022. Not even the tough comps introduced by the first 5G-capable model will likely be enough to steal the thunder of a well-received iPhone 13.</p>\n<p><b>But how about AAPL stock?</b></p>\n<p>Keep in mind that financial performance, especially in the short term, does not always correlate with share price movements. In fact, any impact that the holiday P&amp;L results may have on Apple stock would likely not happen until late January 2022, when the company reports fiscal Q1 earnings.</p>\n<p>For the immediate term, Apple investors should keep in mind that the stock’s&nbsp;seasonal patterns have been historically unfavorable&nbsp;around this time of the year. The chart below shows that AAPL has clearly underperformed in November through January. Will this time be any different? Only time will tell.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a4c72a2f9720f472ceba32b24f4a2a78\" tg-width=\"682\" tg-height=\"357\" width=\"100%\" height=\"auto\"><span>Figure 3: AAPL average monthly return since iPhone launch.</span></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: What to Expect During the Holiday Season</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: What to Expect During the Holiday Season\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 23:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/apple/stock/apple-stock-holiday-season-starts-what-next><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The 2021 holiday shopping season has officially started. Here is what Apple investors should expect of the Cupertino company and its stock in the next few weeks.\nBlack Friday and Cyber Monday are ...</p>\n\n<a href=\"https://www.thestreet.com/apple/stock/apple-stock-holiday-season-starts-what-next\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/stock/apple-stock-holiday-season-starts-what-next","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158390889","content_text":"The 2021 holiday shopping season has officially started. Here is what Apple investors should expect of the Cupertino company and its stock in the next few weeks.\nBlack Friday and Cyber Monday are behind us. With that, the 2021 holiday season in the US and parts of the world has officially begun. Consumer product and service companies like Apple are staring into the busiest weeks of sales in the year.\nFigure 1: Apple's iPhone, Apple Watch and Air Pods boxes.\nToday, the Apple Maven talks about what Apple stock investors should think about as the shopping season kicks into gear.\nApple to benefit from strong consumer\nAt the highest level possible, Apple is likely to benefit from a rising tide that lifts all boats in 2021. The chart below clearly shows that consumer spending in the US has not only recovered from the 2020 flash recession, but it has been “making up for lost time”. Spending trends have even accelerated slightly compared to the pre-pandemic period.\nFigure 2: Consumer spending in US.\nRegarding the holiday period, however, consumer product and service sales may look a bit atypical. Adobe has recently reported that Black Friday activity online dropped year-over-year for the first time ever. Online sales reached $8.9 billion, lower than 2020’s $9 billion.\nWithout context, these numbers may look concerning. But once again, there is nothing typical about this COVID-19 crisis. Black Friday likely suffered from (1) consumers buying earlier than usual, to avoid delayed deliveries in late November and December, and (2) supply chain constraints causing shortages and missed sales opportunities.\nApple could do better than average\nThe demand scenario described above is at least modestly optimistic, in my view, even if not without challenges on the supply side. Even so, I think that Apple has a good chance of performing better than average in the next few weeks.\nFor starters, the Cupertino company is one of the best in the world at managing inventory and supply chain. Consider, however, that CEO Tim Cook has already warned of an impact of $6 billion to revenues in the holiday quarter caused by the production and logistics bottlenecks.\nSecond, the demand for Apple’s products and services seems unshaken.I have discussed a few times that the iPhone, for example, is likely to have its best years of sales ever in fiscal 2021 and 2022. Not even the tough comps introduced by the first 5G-capable model will likely be enough to steal the thunder of a well-received iPhone 13.\nBut how about AAPL stock?\nKeep in mind that financial performance, especially in the short term, does not always correlate with share price movements. In fact, any impact that the holiday P&L results may have on Apple stock would likely not happen until late January 2022, when the company reports fiscal Q1 earnings.\nFor the immediate term, Apple investors should keep in mind that the stock’s seasonal patterns have been historically unfavorable around this time of the year. The chart below shows that AAPL has clearly underperformed in November through January. Will this time be any different? Only time will tell.\nFigure 3: AAPL average monthly return since iPhone launch.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":3021,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878374879,"gmtCreate":1637155859042,"gmtModify":1637155859205,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Hope the new CFO can create breaking amazing accounting...i wish.. like like","listText":"Hope the new CFO can create breaking amazing accounting...i wish.. like like","text":"Hope the new CFO can create breaking amazing accounting...i wish.. like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878374879","repostId":"1174626804","repostType":4,"isVote":1,"tweetType":1,"viewCount":2127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879786388,"gmtCreate":1636773154807,"gmtModify":1636773154970,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Pfizer the old giant ,time to wake upupup...i wish...like like","listText":"Pfizer the old giant ,time to wake upupup...i wish...like like","text":"Pfizer the old giant ,time to wake upupup...i wish...like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/879786388","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://ttm.financial/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845725320,"gmtCreate":1636370468073,"gmtModify":1636370468481,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"nio pls niu niu(bull bull)...like like","listText":"nio pls niu niu(bull bull)...like like","text":"nio pls niu niu(bull bull)...like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845725320","repostId":"1103591841","repostType":4,"repost":{"id":"1103591841","kind":"news","pubTimestamp":1636363932,"share":"https://ttm.financial/m/news/1103591841?lang=&edition=full","pubTime":"2021-11-08 17:32","market":"us","language":"en","title":"NIO share price on watch ahead of Q3 earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1103591841","media":"IG","summary":"When does NIO report earnings?\nNIOis set to release its quarter three (Q3) financial results on 9 No","content":"<p>When does NIO report earnings?</p>\n<p>NIOis set to release its quarter three (Q3) financial results on 9 November 2021, after market closes.</p>\n<p>NIO earnings – what to expect</p>\n<p>Current expectations are for NIO’s upcoming Q3 revenue to come in at RMB 9.3 billion, a 106% increase year-on-year (YoY) and a 10.3% increase quarter-on-quarter. Overall net loss is expected to shrink to RMB 726 million from RMB 996 a year ago, with an improvement in overall margins.</p>\n<p>The ongoing growth momentum for the upcoming quarter may have been reflected in its vehicle deliveries for July-September, where total deliveries for that period saw an increase of 11.6% since quarter two (Q2). October’s delivery numbers may be in focus, where the restructuring of manufacturing lines and preparation for introduction of new products have led to a sharp dip in production. While the impact may not be reflected in the upcoming Q3 results, markets may look out for guidance pertaining to the resumption of production in the upcoming earnings call.</p>\n<p>As the issues seem temporary, some focus may be on overall demand for NIO’s vehicles, which has remained robust with new orders reaching another all-time high in October.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e8f2bf368ae683763e8c36519a1bee6f\" tg-width=\"943\" tg-height=\"589\" width=\"100%\" height=\"auto\"><span>Source: NIO</span></p>\n<p>In line with global supply chain issues, NIO’s production capacity remained capped by shortages of input components, such as semiconductors. A key risk that may further aggravate production capacity ahead may be the recentCovid-19resurgences in China. With China’s zero Covid-19 stance, aggressive measures have previously disrupted production for NIO’s partners located in high-risk areas. With that, markets will be on watch for any guidance from management regarding the supply chain situation, alongside the potential impact from recent Covid-19 risks.</p>\n<p>Growth catalysts for share price may include a list of three new product launches next year, which includes the NIO ET7. As the specific timing and pricing for the other two products have not been laid out yet, this will also remain in focus for the upcoming results.</p>\n<p>Currently, the stock has 26 ‘buy’ recommendations, four ‘holds’ and one ‘sells’. The Bloomberg 12-month consensus target price of $59.00 suggests a potential 16.3% upside from the price at the time of writing.</p>","source":"lsy1627281591670","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NIO share price on watch ahead of Q3 earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNIO share price on watch ahead of Q3 earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-08 17:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.ig.com/en-ch/news-and-trade-ideas/nio-share-price-on-watch-ahead-of-q3-earnings-211103><strong>IG</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When does NIO report earnings?\nNIOis set to release its quarter three (Q3) financial results on 9 November 2021, after market closes.\nNIO earnings – what to expect\nCurrent expectations are for NIO’s ...</p>\n\n<a href=\"https://www.ig.com/en-ch/news-and-trade-ideas/nio-share-price-on-watch-ahead-of-q3-earnings-211103\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://www.ig.com/en-ch/news-and-trade-ideas/nio-share-price-on-watch-ahead-of-q3-earnings-211103","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103591841","content_text":"When does NIO report earnings?\nNIOis set to release its quarter three (Q3) financial results on 9 November 2021, after market closes.\nNIO earnings – what to expect\nCurrent expectations are for NIO’s upcoming Q3 revenue to come in at RMB 9.3 billion, a 106% increase year-on-year (YoY) and a 10.3% increase quarter-on-quarter. Overall net loss is expected to shrink to RMB 726 million from RMB 996 a year ago, with an improvement in overall margins.\nThe ongoing growth momentum for the upcoming quarter may have been reflected in its vehicle deliveries for July-September, where total deliveries for that period saw an increase of 11.6% since quarter two (Q2). October’s delivery numbers may be in focus, where the restructuring of manufacturing lines and preparation for introduction of new products have led to a sharp dip in production. While the impact may not be reflected in the upcoming Q3 results, markets may look out for guidance pertaining to the resumption of production in the upcoming earnings call.\nAs the issues seem temporary, some focus may be on overall demand for NIO’s vehicles, which has remained robust with new orders reaching another all-time high in October.\nSource: NIO\nIn line with global supply chain issues, NIO’s production capacity remained capped by shortages of input components, such as semiconductors. A key risk that may further aggravate production capacity ahead may be the recentCovid-19resurgences in China. With China’s zero Covid-19 stance, aggressive measures have previously disrupted production for NIO’s partners located in high-risk areas. With that, markets will be on watch for any guidance from management regarding the supply chain situation, alongside the potential impact from recent Covid-19 risks.\nGrowth catalysts for share price may include a list of three new product launches next year, which includes the NIO ET7. As the specific timing and pricing for the other two products have not been laid out yet, this will also remain in focus for the upcoming results.\nCurrently, the stock has 26 ‘buy’ recommendations, four ‘holds’ and one ‘sells’. The Bloomberg 12-month consensus target price of $59.00 suggests a potential 16.3% upside from the price at the time of writing.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":1546,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846935260,"gmtCreate":1636038831085,"gmtModify":1636039097935,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"very detailed and well thought analysis,superb thanks...like like...","listText":"very detailed and well thought analysis,superb thanks...like like...","text":"very detailed and well thought analysis,superb thanks...like like...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846935260","repostId":"1168874793","repostType":2,"repost":{"id":"1168874793","kind":"news","pubTimestamp":1636035446,"share":"https://ttm.financial/m/news/1168874793?lang=&edition=full","pubTime":"2021-11-04 22:17","market":"us","language":"en","title":"Ocugen: WHO Approval For Covaxin Is Potentially A Red Herring For Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=1168874793","media":"Seeking Alpha","summary":"Summary\n\nOcugen missed the opportunity to grab an Emergency Use Authorization for Covaxin in the US ","content":"<p><b>Summary</b></p>\n<ul>\n <li>Ocugen missed the opportunity to grab an Emergency Use Authorization for Covaxin in the US earlier this year, but it could still gain an approval via a pivotal immuno-bridging study.</li>\n <li>Meanwhile, Bharat has received WHO approval for Emergency Use Listing, meaning the vaccine can be distributed around the world - but that doesn't directly benefit Ocugen.</li>\n <li>There are numerous possibilities in play, and Ocugen has no shortage of backers and shorts - the stock is up &gt;4,000% in the past year, but has trodden water for several months.</li>\n <li>It's hard to determine what may be in store next for Ocugen shareholders, but if I were one, I'd be holding and hoping. I recap the full story below.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/25648bf13e5cb82880f748129c72261c\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"><span>Klaus Vedfelt/DigitalVision via Getty Images</span></p>\n<p><b>Investment Thesis</b></p>\n<p>Bharat Biotech received an approval from the World Health Organization (\"WHO\") today to join the Emergency Use List (\"EUL\") for vaccines against COVID-19.</p>\n<p>As most investors will know, Ocugen (OCGN) holds the rights to distribute Covaxin in the US on behalf of Bharat, in exchange for a 45% share of all profits. It also has a similar deal in place for Canada, standing to earn 55% of all profits.</p>\n<p>Ocugen investors and shorts will be nervously waiting to see how today's news affects the biotech's share price, which initially jumped to $16, but has fallen to $12 post-market.</p>\n<p>In this post I recap the full story, updated from my&nbsp;last post in June, and offer some ways to think about Ocugen's share price in the short and long term.</p>\n<p><b>Ocugen Stock Jumps From $0.5 To $16 In 3 Months On Bharat COVID Vaccine Deal - The Story So Far</b></p>\n<p>Ocugen is one of the more bizarre biotech stories of 2021. In mid-December 2020, its shares were trading &lt;$0.5, as the company struggled to develop a preclinical portfolio of gene therapy drug candidates targeting eye disease, having abandoned development of its lead candidate OCU300 in Graft vs Host Disease (\"GvHD\").</p>\n<p>A delisting from the Nasdaq looked a likely outcome for the company, but then Ocugen's fortunes changed dramatically - the biotech&nbsp;became a partner&nbsp;of Bharat Biotech, developer of the whole-virion inactivated vaccine candidate Covaxin, agreeing to help the Indian Pharma commercialise Covaxin in the US and Canada. Overnight, Ocugen's share price jumped to a price of $3, and by early February, it was trading at $16.</p>\n<p>I covered the full story in a&nbsp;note on Ocugen&nbsp;back in June, when Ocugen's shares were trading in a slightly more down-to-earth range of $6 - $10. At that time, the key question was whether Covaxin would receive an Emergency Use Authorization (\"EUA\") from the FDA, allowing it to be marketed and sold in the US.</p>\n<p>Unfortunately for Ocugen investors, delays in Bharat's trials of Covaxin in India, where outbreaks of COVID had suddenly become widespread, meant that Ocugen could not get positive Phase 3 trial data in front of the FDA in time for a deadline imposed by the US government - after which it would not accept any further EUA requests for COVID-19 vaccines for the remainder of the pandemic for those companies that have not already begun discussions with the FDA.</p>\n<p><b>Ocugen And Bharat Stay The Course - Trials Reveal Strong Efficacy</b></p>\n<p>The bad news about an EUA in the US did not deter Ocugen, Bharat, or Ocugen's investors, however. Despite heavy short interest, as many market watchers concluded Ocugen's share price would be decimated without an EUA for Covaxin in the US, Ocugen management felt that there were other options on the table, including obtaining an EUA in Canada, which falls under its agreement with Bharat, allowing Ocugen to earn 45% of all revenues earned in the region.</p>\n<p>The results of Bharat's ~@5k patient Phase 3 trial in India also came out positive.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/862520ed53c876fb96840a3cb9a7a6f9\" tg-width=\"640\" tg-height=\"317\" width=\"100%\" height=\"auto\"><span>Summary of results of Bharat Biotech Phase 3 trial of Covaxin. Source: Ocugen Corporate Presentation.</span></p>\n<p>As we can see above, Bharat's Covaxin (finally) delivered an efficacy readout of 77.8%, 93.4% efficacy against severe disease - and 65.2% efficacy against the delta variant - the most devastating of all the COVID strains. Furthermore, the National Institute of Allergies and Infectious Diseases advised that a novel vaccine adjuvant developed in Kansas, US with NIAID support, Alhydroxiquim-II, enhanced the overall efficacy of Covaxin.</p>\n<p><b>Bharat Pursues WHO Emergency Use Listing Whilst Ocugen Looks To Canada</b></p>\n<p>These results, as strong as they are - and it should be noted the efficacy of Pfizer (PFE) and BioNTech's (BNTX) messenger-RNA Comirnaty vaccine against the Delta variant has&nbsp;dropped as low as 39%&nbsp;in studies in Israel - they arrived too late to help Ocugen secure an EUA in the US.</p>\n<p>Ocugen turned its attention to Canada,announcing&nbsp;a rolling submission to Health Canada on July 15 through its affiliate, Vaccigen, Ltd<b>,</b>allowing for it to submit new data as and when it came in, accelerating the overall review process.</p>\n<p>If approved, Ocugen will earn 55% of all profits earned from the vaccine, but as I discussed in my&nbsp;last note when providing some discounted cash flow analysis&nbsp;based on optimistic and pessimistic scenarios, it's doubtful if the Canadian government's purchases alone would provide a significant boot to Ocugen's current market cap valuation of $2.5bn, or its share price of $12.7.</p>\n<p>The US is the key for Ocugen, and management has by no means given up on this opportunity. In late October, Ocugen made an Investigational New Drug (\"IND\")&nbsp;submission&nbsp;to the FDA. Ocugen's plan is to initiate a Phase 3 \"immuno-bridging study,\" enrolling several hundred healthy adults in the U.S, who will receive 2 doses of Covaxin or placebo, 28 days apart. The endpoints are described by management (in an October 27th press release) as follows:</p>\n<blockquote>\n The primary endpoint will compare blood-based samples taken from U.S. participants who received COVAXIN™ with samples of the participants in the Phase 3 efficacy trial conducted in India. The secondary endpoint involves testing the vaccine's immunogenic profile. The study will also evaluate safety and tolerability in the U.S. population.\n</blockquote>\n<p>Ocugen hopes to have the study complete before the end of H122, if it is approved by the FDA, which has yet to make a decision. If the FDA does give the green light, then the US market - and Ocugen's 45% of all profits - is suddenly back on the table.</p>\n<p>Meanwhile, Bharat Biotech&nbsp;received notification&nbsp;today that the World Health Organization has approved its application for an Emergency Use Listing (\"EUL\"), meaning Covaxin will now likely be accepted by a host of foreign governments, and that Indians who have received the vaccine will have fewer problems traveling overseas.</p>\n<p>It's great news for Bharat, who join the likes of Pfizer / BioNTech, Johnson &amp; Johnson (JNJ), SinoPharm, Moderna (MRNA) and AstraZeneca (AZN) on the list of EUL-approved vaccine developers - but it is not necessarily great news for Ocugen.</p>\n<p>Vaccines on the EUL list are permitted to be sent to government's around the world as part of the&nbsp;COVAX scheme, designed to create equitable vaccine distribution around the world, including poorer countries, but the US is a donor to this scheme, not a beneficiary, meaning that Ocugen effectively gets no benefit, and no revenues, as a result of the WHO approval for Covaxin.</p>\n<p><b>Ocugen Stock Is Already On A Downtrend - All Eyes Will Now Be On Health Canada And The FDA</b></p>\n<p>Ocugen stock bounced from a price of ~$9, to a peak of ~$16 in trading today, however the share price quickly began to decline, and finished at a price of $12.7. Post-market, shares were down another 10%.</p>\n<p>That reflects the fact that the WHO approval for Covaxin does little to improve Ocugen's own fortunes, and in all honesty, was something of a red herring.</p>\n<p>Ocugen investors, and Ocugen shorts, are desperate to know what the future holds for Covaxin in the US and Canada, but they will have to wait until Health Canada and the FDA rule respectively on an Emergency Use Authorization, and an approval to begin a drastically reduced pivotal trial in the US.</p>\n<p>Ironically, despite all of the news flow and the publication of Covaxin Phase 3 trial data, and the EUA granted to Covaxin by the Indian government, Ocugen's fortunes are in a similar place to where they were when I last covered the company - barring the US EUA opportunity.</p>\n<p>That opportunity - the one that may have sent Ocugen shares through the roof - has gone, but as I argued in my last post, I think it's possible that the US would not object to stockpiling some of the Covaxin shot, which has a differentiated mechanism of action, and a shelf life of up to years if stored at 2- 8 degrees centigrade.</p>\n<p>Covaxin may have benefits that other vaccines do not, the reasoning may go, such as its ability to induce a Th1 response, conferring cell-mediated immunity and offering durable protection, and enhanced protection against COVID variants, which is the primary concern at the present time.</p>\n<p>On the other hand, the US may now be able to obtain supply directly from Bharat via the WHO and be in a position to cut Ocugen - the middleman - out of any deal.</p>\n<p>The fact of the matter is that Ocugen's opportunity with Bharat and Covaxin has always appeared to be one that required expediency of execution, in order to capitalize on a US market opportunity that's uncertain, perhaps negligible, at worst, and a potential multi-billion opportunity at best.</p>\n<p>Nobody knows even if Ocugen will get an opportunity to market Covaxin in the US, but if it does, it will need to negotiate a tricky Phase 3 trial first, which could take us into the latter half of next year. Equally, no-one yet knows if Health Canada will approve the vaccine.</p>\n<p><b>Conclusion</b></p>\n<p>To summarise the current state of affairs, I would lean toward an approval in Canada - if Covaxin is good enough for the WHO, why would it not be good enough for Canada?</p>\n<p>But how much product will Canada buy? Probably enough to create a substantial price spike for Ocugen stock, although demand is unlikely to be high enough to sustain that spike long term.</p>\n<p>How much would the US buy if Covaxin was approved in the US? Again, I cannot see it being a high enough volume to catapult Ocugen's market cap above say $10bn, but if it buys any at all, Ocugen's market valuation is more or less guaranteed to surge, at least temporarily.</p>\n<p>In conclusion, I would argue that there is enough intrigue and opportunity in the Ocugen story to keep investors interested - on both the short and long sides. The WHO approval does not directly benefit Ocugen revenues wise, but it's another win for Covaxin, which is in turn a win for Ocugen.</p>\n<p>If I has been holding Ocugen stock since December last year, when it traded at &gt;$0.5, frankly I would have sold by now, but if I had opened a position at ~$10, in expectation of doubling my money on a US approval, I would still be (nervously) holding.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen: WHO Approval For Covaxin Is Potentially A Red Herring For Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen: WHO Approval For Covaxin Is Potentially A Red Herring For Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-04 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4465154-ocugen-approval-for-covaxin-red-herring-for-investors><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nOcugen missed the opportunity to grab an Emergency Use Authorization for Covaxin in the US earlier this year, but it could still gain an approval via a pivotal immuno-bridging study.\n...</p>\n\n<a href=\"https://seekingalpha.com/article/4465154-ocugen-approval-for-covaxin-red-herring-for-investors\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://seekingalpha.com/article/4465154-ocugen-approval-for-covaxin-red-herring-for-investors","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168874793","content_text":"Summary\n\nOcugen missed the opportunity to grab an Emergency Use Authorization for Covaxin in the US earlier this year, but it could still gain an approval via a pivotal immuno-bridging study.\nMeanwhile, Bharat has received WHO approval for Emergency Use Listing, meaning the vaccine can be distributed around the world - but that doesn't directly benefit Ocugen.\nThere are numerous possibilities in play, and Ocugen has no shortage of backers and shorts - the stock is up >4,000% in the past year, but has trodden water for several months.\nIt's hard to determine what may be in store next for Ocugen shareholders, but if I were one, I'd be holding and hoping. I recap the full story below.\n\nKlaus Vedfelt/DigitalVision via Getty Images\nInvestment Thesis\nBharat Biotech received an approval from the World Health Organization (\"WHO\") today to join the Emergency Use List (\"EUL\") for vaccines against COVID-19.\nAs most investors will know, Ocugen (OCGN) holds the rights to distribute Covaxin in the US on behalf of Bharat, in exchange for a 45% share of all profits. It also has a similar deal in place for Canada, standing to earn 55% of all profits.\nOcugen investors and shorts will be nervously waiting to see how today's news affects the biotech's share price, which initially jumped to $16, but has fallen to $12 post-market.\nIn this post I recap the full story, updated from my last post in June, and offer some ways to think about Ocugen's share price in the short and long term.\nOcugen Stock Jumps From $0.5 To $16 In 3 Months On Bharat COVID Vaccine Deal - The Story So Far\nOcugen is one of the more bizarre biotech stories of 2021. In mid-December 2020, its shares were trading <$0.5, as the company struggled to develop a preclinical portfolio of gene therapy drug candidates targeting eye disease, having abandoned development of its lead candidate OCU300 in Graft vs Host Disease (\"GvHD\").\nA delisting from the Nasdaq looked a likely outcome for the company, but then Ocugen's fortunes changed dramatically - the biotech became a partner of Bharat Biotech, developer of the whole-virion inactivated vaccine candidate Covaxin, agreeing to help the Indian Pharma commercialise Covaxin in the US and Canada. Overnight, Ocugen's share price jumped to a price of $3, and by early February, it was trading at $16.\nI covered the full story in a note on Ocugen back in June, when Ocugen's shares were trading in a slightly more down-to-earth range of $6 - $10. At that time, the key question was whether Covaxin would receive an Emergency Use Authorization (\"EUA\") from the FDA, allowing it to be marketed and sold in the US.\nUnfortunately for Ocugen investors, delays in Bharat's trials of Covaxin in India, where outbreaks of COVID had suddenly become widespread, meant that Ocugen could not get positive Phase 3 trial data in front of the FDA in time for a deadline imposed by the US government - after which it would not accept any further EUA requests for COVID-19 vaccines for the remainder of the pandemic for those companies that have not already begun discussions with the FDA.\nOcugen And Bharat Stay The Course - Trials Reveal Strong Efficacy\nThe bad news about an EUA in the US did not deter Ocugen, Bharat, or Ocugen's investors, however. Despite heavy short interest, as many market watchers concluded Ocugen's share price would be decimated without an EUA for Covaxin in the US, Ocugen management felt that there were other options on the table, including obtaining an EUA in Canada, which falls under its agreement with Bharat, allowing Ocugen to earn 45% of all revenues earned in the region.\nThe results of Bharat's ~@5k patient Phase 3 trial in India also came out positive.\nSummary of results of Bharat Biotech Phase 3 trial of Covaxin. Source: Ocugen Corporate Presentation.\nAs we can see above, Bharat's Covaxin (finally) delivered an efficacy readout of 77.8%, 93.4% efficacy against severe disease - and 65.2% efficacy against the delta variant - the most devastating of all the COVID strains. Furthermore, the National Institute of Allergies and Infectious Diseases advised that a novel vaccine adjuvant developed in Kansas, US with NIAID support, Alhydroxiquim-II, enhanced the overall efficacy of Covaxin.\nBharat Pursues WHO Emergency Use Listing Whilst Ocugen Looks To Canada\nThese results, as strong as they are - and it should be noted the efficacy of Pfizer (PFE) and BioNTech's (BNTX) messenger-RNA Comirnaty vaccine against the Delta variant has dropped as low as 39% in studies in Israel - they arrived too late to help Ocugen secure an EUA in the US.\nOcugen turned its attention to Canada,announcing a rolling submission to Health Canada on July 15 through its affiliate, Vaccigen, Ltd,allowing for it to submit new data as and when it came in, accelerating the overall review process.\nIf approved, Ocugen will earn 55% of all profits earned from the vaccine, but as I discussed in my last note when providing some discounted cash flow analysis based on optimistic and pessimistic scenarios, it's doubtful if the Canadian government's purchases alone would provide a significant boot to Ocugen's current market cap valuation of $2.5bn, or its share price of $12.7.\nThe US is the key for Ocugen, and management has by no means given up on this opportunity. In late October, Ocugen made an Investigational New Drug (\"IND\") submission to the FDA. Ocugen's plan is to initiate a Phase 3 \"immuno-bridging study,\" enrolling several hundred healthy adults in the U.S, who will receive 2 doses of Covaxin or placebo, 28 days apart. The endpoints are described by management (in an October 27th press release) as follows:\n\n The primary endpoint will compare blood-based samples taken from U.S. participants who received COVAXIN™ with samples of the participants in the Phase 3 efficacy trial conducted in India. The secondary endpoint involves testing the vaccine's immunogenic profile. The study will also evaluate safety and tolerability in the U.S. population.\n\nOcugen hopes to have the study complete before the end of H122, if it is approved by the FDA, which has yet to make a decision. If the FDA does give the green light, then the US market - and Ocugen's 45% of all profits - is suddenly back on the table.\nMeanwhile, Bharat Biotech received notification today that the World Health Organization has approved its application for an Emergency Use Listing (\"EUL\"), meaning Covaxin will now likely be accepted by a host of foreign governments, and that Indians who have received the vaccine will have fewer problems traveling overseas.\nIt's great news for Bharat, who join the likes of Pfizer / BioNTech, Johnson & Johnson (JNJ), SinoPharm, Moderna (MRNA) and AstraZeneca (AZN) on the list of EUL-approved vaccine developers - but it is not necessarily great news for Ocugen.\nVaccines on the EUL list are permitted to be sent to government's around the world as part of the COVAX scheme, designed to create equitable vaccine distribution around the world, including poorer countries, but the US is a donor to this scheme, not a beneficiary, meaning that Ocugen effectively gets no benefit, and no revenues, as a result of the WHO approval for Covaxin.\nOcugen Stock Is Already On A Downtrend - All Eyes Will Now Be On Health Canada And The FDA\nOcugen stock bounced from a price of ~$9, to a peak of ~$16 in trading today, however the share price quickly began to decline, and finished at a price of $12.7. Post-market, shares were down another 10%.\nThat reflects the fact that the WHO approval for Covaxin does little to improve Ocugen's own fortunes, and in all honesty, was something of a red herring.\nOcugen investors, and Ocugen shorts, are desperate to know what the future holds for Covaxin in the US and Canada, but they will have to wait until Health Canada and the FDA rule respectively on an Emergency Use Authorization, and an approval to begin a drastically reduced pivotal trial in the US.\nIronically, despite all of the news flow and the publication of Covaxin Phase 3 trial data, and the EUA granted to Covaxin by the Indian government, Ocugen's fortunes are in a similar place to where they were when I last covered the company - barring the US EUA opportunity.\nThat opportunity - the one that may have sent Ocugen shares through the roof - has gone, but as I argued in my last post, I think it's possible that the US would not object to stockpiling some of the Covaxin shot, which has a differentiated mechanism of action, and a shelf life of up to years if stored at 2- 8 degrees centigrade.\nCovaxin may have benefits that other vaccines do not, the reasoning may go, such as its ability to induce a Th1 response, conferring cell-mediated immunity and offering durable protection, and enhanced protection against COVID variants, which is the primary concern at the present time.\nOn the other hand, the US may now be able to obtain supply directly from Bharat via the WHO and be in a position to cut Ocugen - the middleman - out of any deal.\nThe fact of the matter is that Ocugen's opportunity with Bharat and Covaxin has always appeared to be one that required expediency of execution, in order to capitalize on a US market opportunity that's uncertain, perhaps negligible, at worst, and a potential multi-billion opportunity at best.\nNobody knows even if Ocugen will get an opportunity to market Covaxin in the US, but if it does, it will need to negotiate a tricky Phase 3 trial first, which could take us into the latter half of next year. Equally, no-one yet knows if Health Canada will approve the vaccine.\nConclusion\nTo summarise the current state of affairs, I would lean toward an approval in Canada - if Covaxin is good enough for the WHO, why would it not be good enough for Canada?\nBut how much product will Canada buy? Probably enough to create a substantial price spike for Ocugen stock, although demand is unlikely to be high enough to sustain that spike long term.\nHow much would the US buy if Covaxin was approved in the US? Again, I cannot see it being a high enough volume to catapult Ocugen's market cap above say $10bn, but if it buys any at all, Ocugen's market valuation is more or less guaranteed to surge, at least temporarily.\nIn conclusion, I would argue that there is enough intrigue and opportunity in the Ocugen story to keep investors interested - on both the short and long sides. The WHO approval does not directly benefit Ocugen revenues wise, but it's another win for Covaxin, which is in turn a win for Ocugen.\nIf I has been holding Ocugen stock since December last year, when it traded at >$0.5, frankly I would have sold by now, but if I had opened a position at ~$10, in expectation of doubling my money on a US approval, I would still be (nervously) holding.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849574363,"gmtCreate":1635770699230,"gmtModify":1635771432150,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Just a thinker, will the masses need credit card like Mastercard Visa Amex when anyone&nbsp;can BNPL on those online&nbsp;shops? .... like like","listText":"Just a thinker, will the masses need credit card like Mastercard Visa Amex when anyone&nbsp;can BNPL on those online&nbsp;shops? .... like like","text":"Just a thinker, will the masses need credit card like Mastercard Visa Amex when anyone can BNPL on those online shops? .... like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849574363","repostId":"2179806221","repostType":4,"repost":{"id":"2179806221","kind":"highlight","pubTimestamp":1635759401,"share":"https://ttm.financial/m/news/2179806221?lang=&edition=full","pubTime":"2021-11-01 17:36","market":"us","language":"en","title":"3 Warren Buffett Stocks to Buy in November","url":"https://stock-news.laohu8.com/highlight/detail?id=2179806221","media":"Motley Fool","summary":"They're all big winners in recent years that are poised to be even bigger winners over the long term.","content":"<p>You could probably sum up the secret to Warren Buffett's success in three words: Think long term. That's what the legendary investor has done throughout his storied career -- even before he took the helm at <b>Berkshire Hathaway</b>&nbsp;(NYSE:BRK.A) (NYSE:BRK.B).</p>\n<p>It's also exactly what anyone should do when contemplating buying any of the stocks in Buffett's own portfolio. The best of those Berkshire holdings have strong long-term growth prospects. With that in mind, here are three Buffett stocks to buy in November.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F648032%2Fwarren-buffett-tmf-photo.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: The Motley Fool.</span></p>\n<h2>1. Amazon.com</h2>\n<p><b>Amazon.com</b> (NASDAQ:AMZN) founder Jeff Bezos likes to say that \"it's still Day 1.\" By that, he means that the company retains the mentality of its first day as a start-up. This is the kind of guiding philosophy that could propel this FAANG stock much higher even though Amazon's market cap already tops $1.7 trillion.</p>\n<p>There's actually a good reason for investors to think about Amazon with a \"Day 1\" perspective as well. Sure, the company reigns as the 800-pound gorilla in e-commerce. However, U.S. e-commerce sales in the second quarter of 2021 made up only 12.5% of total retail sales. Amazon still has huge growth potential in this core market.</p>\n<p>The company has even more opportunities with Amazon Web Services (AWS). This cloud business remains a tremendous growth driver despite intensifying competition.</p>\n<p>And it truly is Day 1 for Amazon in multiple other areas. The company launched its telehealth service this summer. It recently rolled out its first robot -- a dog named Astro. Amazon also has the potential to expand in video games, self-driving car technology, and more.</p>\n<h2>2. Apple</h2>\n<p>One thing Buffett never does is obsess about <a href=\"https://laohu8.com/S/AONE.U\">one</a> quarterly update. That's a lesson every investor should follow, especially in the case of&nbsp;<b>Apple</b>'s (NASDAQ:AAPL) fiscal 2021 fourth-quarter sales miss.</p>\n<p>Sure, Apple didn't generate the revenue that Wall Street expected. However, the problem was supply constraints caused by a global chip shortage and manufacturing disruptions in Southeast Asia due to COVID-19. Those are only temporary issues. And Apple still managed to grow revenue 29% year over year despite the headwinds.</p>\n<p>More important, the company's long-term prospects remain strong. Apple's iPhone ecosystem is as sticky as ever. Its services business is especially gaining momentum. The increased adoption of high-speed 5G networks continues to fuel demand for the company's products. Over the next decade, I expect that augmented reality will become another major growth driver for Apple's ecosystem.</p>\n<p>The current chip shortage and COVID-19's impact on manufacturing won't matter in the near future. You can bet that Buffett isn't selling any of his Apple shares on the latest pullback. I wouldn't be surprised if he's instead buying more of the top stock in Berkshire's portfolio.</p>\n<h2>3. Mastercard</h2>\n<p>Unlike Apple,&nbsp;<b>Mastercard</b> (NYSE:MA) beat expectations in its latest quarterly update. The financial services giant delivered 30% revenue growth with earnings soaring 59%.</p>\n<p>Again, though, the snapshot of what the company has already done isn't nearly as critical as what its future prospects are. And Mastercard's future still looks very bright, particularly with several new initiatives.</p>\n<p>Mastercard Installments puts the company at the center of the fast-growing \"buy now, pay later\" opportunity. The new service can be used anywhere across the Mastercard network, both online and in stores.</p>\n<p>The company's acquisition of CipherTrace bolsters its expansion of cryptocurrency services. Its pending buyout of European technology provider Aiia extends Mastercard's efforts in leading the way in open banking, which enables consumers and businesses to use their data to get financial services easily and securely.</p>\n<p>These new products and deals reinforce the key role that Mastercard plays in the transition from cash to digital payments. Mastercard is a Buffett stock that you can buy in November and hold forever.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Warren Buffett Stocks to Buy in November</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Warren Buffett Stocks to Buy in November\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-01 17:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/31/3-warren-buffett-stocks-to-buy-in-november/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You could probably sum up the secret to Warren Buffett's success in three words: Think long term. That's what the legendary investor has done throughout his storied career -- even before he took the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/31/3-warren-buffett-stocks-to-buy-in-november/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","MA":"万事达"},"source_url":"https://www.fool.com/investing/2021/10/31/3-warren-buffett-stocks-to-buy-in-november/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2179806221","content_text":"You could probably sum up the secret to Warren Buffett's success in three words: Think long term. That's what the legendary investor has done throughout his storied career -- even before he took the helm at Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B).\nIt's also exactly what anyone should do when contemplating buying any of the stocks in Buffett's own portfolio. The best of those Berkshire holdings have strong long-term growth prospects. With that in mind, here are three Buffett stocks to buy in November.\nImage source: The Motley Fool.\n1. Amazon.com\nAmazon.com (NASDAQ:AMZN) founder Jeff Bezos likes to say that \"it's still Day 1.\" By that, he means that the company retains the mentality of its first day as a start-up. This is the kind of guiding philosophy that could propel this FAANG stock much higher even though Amazon's market cap already tops $1.7 trillion.\nThere's actually a good reason for investors to think about Amazon with a \"Day 1\" perspective as well. Sure, the company reigns as the 800-pound gorilla in e-commerce. However, U.S. e-commerce sales in the second quarter of 2021 made up only 12.5% of total retail sales. Amazon still has huge growth potential in this core market.\nThe company has even more opportunities with Amazon Web Services (AWS). This cloud business remains a tremendous growth driver despite intensifying competition.\nAnd it truly is Day 1 for Amazon in multiple other areas. The company launched its telehealth service this summer. It recently rolled out its first robot -- a dog named Astro. Amazon also has the potential to expand in video games, self-driving car technology, and more.\n2. Apple\nOne thing Buffett never does is obsess about one quarterly update. That's a lesson every investor should follow, especially in the case of Apple's (NASDAQ:AAPL) fiscal 2021 fourth-quarter sales miss.\nSure, Apple didn't generate the revenue that Wall Street expected. However, the problem was supply constraints caused by a global chip shortage and manufacturing disruptions in Southeast Asia due to COVID-19. Those are only temporary issues. And Apple still managed to grow revenue 29% year over year despite the headwinds.\nMore important, the company's long-term prospects remain strong. Apple's iPhone ecosystem is as sticky as ever. Its services business is especially gaining momentum. The increased adoption of high-speed 5G networks continues to fuel demand for the company's products. Over the next decade, I expect that augmented reality will become another major growth driver for Apple's ecosystem.\nThe current chip shortage and COVID-19's impact on manufacturing won't matter in the near future. You can bet that Buffett isn't selling any of his Apple shares on the latest pullback. I wouldn't be surprised if he's instead buying more of the top stock in Berkshire's portfolio.\n3. Mastercard\nUnlike Apple, Mastercard (NYSE:MA) beat expectations in its latest quarterly update. The financial services giant delivered 30% revenue growth with earnings soaring 59%.\nAgain, though, the snapshot of what the company has already done isn't nearly as critical as what its future prospects are. And Mastercard's future still looks very bright, particularly with several new initiatives.\nMastercard Installments puts the company at the center of the fast-growing \"buy now, pay later\" opportunity. The new service can be used anywhere across the Mastercard network, both online and in stores.\nThe company's acquisition of CipherTrace bolsters its expansion of cryptocurrency services. Its pending buyout of European technology provider Aiia extends Mastercard's efforts in leading the way in open banking, which enables consumers and businesses to use their data to get financial services easily and securely.\nThese new products and deals reinforce the key role that Mastercard plays in the transition from cash to digital payments. Mastercard is a Buffett stock that you can buy in November and hold forever.","news_type":1,"symbols_score_info":{"AAPL":0.9,"MA":0.9}},"isVote":1,"tweetType":1,"viewCount":3956,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849544133,"gmtCreate":1635770044164,"gmtModify":1635770044282,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/F\">$Ford(F)$</a>csuch an old time car company yet stock price is just a fraction of Tesla's, Ford need to employ dreamers management but still give dividends hor..i wish ...like like...","listText":"<a href=\"https://laohu8.com/S/F\">$Ford(F)$</a>csuch an old time car company yet stock price is just a fraction of Tesla's, Ford need to employ dreamers management but still give dividends hor..i wish ...like like...","text":"$Ford(F)$csuch an old time car company yet stock price is just a fraction of Tesla's, Ford need to employ dreamers management but still give dividends hor..i wish ...like like...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849544133","isVote":1,"tweetType":1,"viewCount":3020,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859459142,"gmtCreate":1634724598127,"gmtModify":1634724733333,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"nio niu (bullish) yah... like like","listText":"nio niu (bullish) yah... like like","text":"nio niu (bullish) yah... like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/859459142","repostId":"2176832734","repostType":4,"repost":{"id":"2176832734","kind":"news","pubTimestamp":1634721059,"share":"https://ttm.financial/m/news/2176832734?lang=&edition=full","pubTime":"2021-10-20 17:10","market":"us","language":"en","title":"NIO May Bring ET7's Electric Drive System To All Models: Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2176832734","media":"Benzinga","summary":"Chinese electric vehicle maker Nio Inc (NYSE: NIO) may introduce its electric sedan ET7’s electric d","content":"<p><img src=\"https://static.tigerbbs.com/747ca2d6065a7a14c35dbba18ac30ac6\" tg-width=\"600\" tg-height=\"400\" referrerpolicy=\"no-referrer\"></p>\n<p>Chinese electric vehicle maker <b>Nio Inc</b> (NYSE: NIO) may introduce its electric sedan ET7’s electric drive system to all models, cnEVpost reported on Tuesday, citing a Chinese news publication.</p>\n<p><b>What Happened: </b>The Shanghai-headquartered Nio may bring the second-generation electric motor to other models such as the ES8, ES6 and EC6, as per reports coming from China.</p>\n<p>The electric drive system has a combined system power of 480kW — 180kW at the front and 300kW at the rear — and a peak torque of 850 Nm.</p>\n<p><i>See Also: Nio Prices ES8 SUV Lower In Norway Than Home Country China, Unveils Nio House In Oslo</i></p>\n<p><b>Why It Matters:</b>&nbsp;Nio, founded in 2014,&nbsp;launched the flagship sedan ET7 in January at the company’s annual day, complete with its second-generation electric drive system.</p>\n<p>This system utilizes&nbsp;<b>silicon carbide (SiC),</b>&nbsp;which is considered more efficient, lightweight and compact than silicon. Rival&nbsp;<b>Tesla Inc</b> (NASDAQ: TSLA)&nbsp;was the first to use SiC of all peers, putting chips made of the world's third-hardest substance in inverters of some Model 3 vehicles, Nikkei Asia reported last month.</p>\n<p>Nio is among a growing breed of homegrown Chinese electric vehicle startups beside&nbsp;<b>Xpeng Inc</b> (NYSE: XPEV) and&nbsp;<b>Li Auto Inc&nbsp;</b>(NASDAQ: LI),&nbsp;which have quickly established themselves locally with their all-electric lineup&nbsp;and are now eyeing international expansion.</p>\n<p>In May, the electric vehicle maker revealed plans to expand to markets outside of China, starting with Norway.</p>\n<p><b>Price Action:</b> Nio shares closed 1.06% higher at $40.03 a share on Tuesday.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NIO May Bring ET7's Electric Drive System To All Models: Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNIO May Bring ET7's Electric Drive System To All Models: Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-20 17:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/nio-may-bring-et7s-electric-024359218.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese electric vehicle maker Nio Inc (NYSE: NIO) may introduce its electric sedan ET7’s electric drive system to all models, cnEVpost reported on Tuesday, citing a Chinese news publication.\nWhat ...</p>\n\n<a href=\"https://finance.yahoo.com/news/nio-may-bring-et7s-electric-024359218.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://finance.yahoo.com/news/nio-may-bring-et7s-electric-024359218.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2176832734","content_text":"Chinese electric vehicle maker Nio Inc (NYSE: NIO) may introduce its electric sedan ET7’s electric drive system to all models, cnEVpost reported on Tuesday, citing a Chinese news publication.\nWhat Happened: The Shanghai-headquartered Nio may bring the second-generation electric motor to other models such as the ES8, ES6 and EC6, as per reports coming from China.\nThe electric drive system has a combined system power of 480kW — 180kW at the front and 300kW at the rear — and a peak torque of 850 Nm.\nSee Also: Nio Prices ES8 SUV Lower In Norway Than Home Country China, Unveils Nio House In Oslo\nWhy It Matters: Nio, founded in 2014, launched the flagship sedan ET7 in January at the company’s annual day, complete with its second-generation electric drive system.\nThis system utilizes silicon carbide (SiC), which is considered more efficient, lightweight and compact than silicon. Rival Tesla Inc (NASDAQ: TSLA) was the first to use SiC of all peers, putting chips made of the world's third-hardest substance in inverters of some Model 3 vehicles, Nikkei Asia reported last month.\nNio is among a growing breed of homegrown Chinese electric vehicle startups beside Xpeng Inc (NYSE: XPEV) and Li Auto Inc (NASDAQ: LI), which have quickly established themselves locally with their all-electric lineup and are now eyeing international expansion.\nIn May, the electric vehicle maker revealed plans to expand to markets outside of China, starting with Norway.\nPrice Action: Nio shares closed 1.06% higher at $40.03 a share on Tuesday.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":2186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850104382,"gmtCreate":1634563119706,"gmtModify":1634563120160,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"very good effort writeup, but layman like me best wish is yoursuggestion what price buy ,what price sell,no obligation jus indication haha thanks,like like....","listText":"very good effort writeup, but layman like me best wish is yoursuggestion what price buy ,what price sell,no obligation jus indication haha thanks,like like....","text":"very good effort writeup, but layman like me best wish is yoursuggestion what price buy ,what price sell,no obligation jus indication haha thanks,like like....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850104382","repostId":"1127670394","repostType":4,"isVote":1,"tweetType":1,"viewCount":1728,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850359594,"gmtCreate":1634558647174,"gmtModify":1634558864198,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"marketing power to the moon......like like","listText":"marketing power to the moon......like like","text":"marketing power to the moon......like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850359594","repostId":"1173638261","repostType":4,"isVote":1,"tweetType":1,"viewCount":513,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850350845,"gmtCreate":1634558522792,"gmtModify":1634558523172,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"$20 by New Year Day...i wish.. like like","listText":"$20 by New Year Day...i wish.. like like","text":"$20 by New Year Day...i wish.. like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850350845","repostId":"1196013286","repostType":4,"repost":{"id":"1196013286","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1634555348,"share":"https://ttm.financial/m/news/1196013286?lang=&edition=full","pubTime":"2021-10-18 19:09","market":"us","language":"en","title":"Ford To Invest $316M On UK EV Plant","url":"https://stock-news.laohu8.com/highlight/detail?id=1196013286","media":"Benzinga","summary":"Ford Motor Co aims to invest up to £230 million ($316 million) to build electric car components at i","content":"<p><b><a href=\"https://laohu8.com/S/F\">Ford</a> Motor Co</b>&nbsp;aims to invest up to £230 million ($316 million) to build electric car components at its Halewood factory in northern England,&nbsp;Reuters reports.</p>\n<p>The Ford plant will produce ~250,000 power units a year from mid-2024, the first European in-house location to make electric vehicle parts for Ford, the report adds.</p>\n<p>\"This is an important step, marking Ford's first in-house investment in all-electric vehicle component manufacturing in Europe,\" Ford's Europe President Stuart Rowley said.</p>\n<p>The government is contributing to the investment through its Automotive Transformation Fund.</p>\n<p>Ford also has a transmission facility in Cologne, Germany. Halewood, which employs about 500 people.</p>\n<p><b>Price Action:</b>&nbsp;F shares closed higher by 1.23% at $15.70 on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ford To Invest $316M On UK EV Plant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFord To Invest $316M On UK EV Plant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-10-18 19:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b><a href=\"https://laohu8.com/S/F\">Ford</a> Motor Co</b>&nbsp;aims to invest up to £230 million ($316 million) to build electric car components at its Halewood factory in northern England,&nbsp;Reuters reports.</p>\n<p>The Ford plant will produce ~250,000 power units a year from mid-2024, the first European in-house location to make electric vehicle parts for Ford, the report adds.</p>\n<p>\"This is an important step, marking Ford's first in-house investment in all-electric vehicle component manufacturing in Europe,\" Ford's Europe President Stuart Rowley said.</p>\n<p>The government is contributing to the investment through its Automotive Transformation Fund.</p>\n<p>Ford also has a transmission facility in Cologne, Germany. Halewood, which employs about 500 people.</p>\n<p><b>Price Action:</b>&nbsp;F shares closed higher by 1.23% at $15.70 on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196013286","content_text":"Ford Motor Co aims to invest up to £230 million ($316 million) to build electric car components at its Halewood factory in northern England, Reuters reports.\nThe Ford plant will produce ~250,000 power units a year from mid-2024, the first European in-house location to make electric vehicle parts for Ford, the report adds.\n\"This is an important step, marking Ford's first in-house investment in all-electric vehicle component manufacturing in Europe,\" Ford's Europe President Stuart Rowley said.\nThe government is contributing to the investment through its Automotive Transformation Fund.\nFord also has a transmission facility in Cologne, Germany. Halewood, which employs about 500 people.\nPrice Action: F shares closed higher by 1.23% at $15.70 on Friday.","news_type":1,"symbols_score_info":{"F":0.9}},"isVote":1,"tweetType":1,"viewCount":763,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827862889,"gmtCreate":1634444122203,"gmtModify":1634444122656,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"sea tsunami up up up ....like like","listText":"sea tsunami up up up ....like like","text":"sea tsunami up up up ....like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/827862889","repostId":"2175112192","repostType":4,"repost":{"id":"2175112192","kind":"highlight","pubTimestamp":1634312035,"share":"https://ttm.financial/m/news/2175112192?lang=&edition=full","pubTime":"2021-10-15 23:33","market":"us","language":"en","title":"5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2175112192","media":"Motley Fool","summary":"These well-known and widely held companies should deliver jaw-dropping revenue growth over the next five years.","content":"<p>Since the Great Recession ended more than 12 years ago, growth stocks have ruled the roost on Wall Street. A combination of historically low lending rates and ongoing quantitative easing measures from the Federal Reserve have rolled out the red carpet for fast-paced companies and given them access to abundant cheap capital.</p>\n<p>Yet for some high-growth stocks, their parabolic sales increases are just beginning. Based on analysts' consensus sales estimates, the following five big-name stocks are expected to increase their sales by 356% to as much as 1,605% by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Ffinancial-newspaper-graph-showing-gains-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Shopify: 464% implied sales growth by 2025</h2>\n<p>The first well-known hypergrowth stock that could deliver a jaw-dropping sales increase over the next five years is cloud-based e-commerce platform <b>Shopify</b> (NYSE:SHOP). Following $2.93 billion in full-year sales in 2020, Wall Street is forecasting $16.54 billion in annual sales by mid-decade. That's a 464% increase, for those of you keeping score at home.</p>\n<p>The beauty of the Shopify operating model is that it finds itself in the right place at the right time. Prior to 2020, businesses were shifting their presence online at a steady pace. But in the wake of the pandemic, businesses of all sizes have come to realize how important it is to have their products available for sale on e-commerce marketplaces. Known best for helping small merchants reach large audiences, Shopify estimates its total addressable market for small businesses is currently $153 billion. Thus, with $2.9 billion in sales last year and the company constantly innovating and introducing new tools, it's just scratching the tip of the iceberg in terms of its potential.</p>\n<p>What's more, Shopify is benefiting from its high-margin subscription-based services. Whereas entrepreneurs can take advantage of the company's basic services for $29 a month, it offers its core service to small businesses for $79/mo. to $299/mo., or its Shopify Plus service for $2,000/mo. to larger businesses. This is a company that shouldn't have any issue growing its operating margins over time.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Ftelemedicine-patient-doctor-physician-virtual-conference-healthcare-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teladoc Health: 356% implied sales growth by 2025</h2>\n<p>Another big-name stock on track to produce eye-popping sales growth over the next half-decade is telemedicine kingpin <b>Teladoc Health</b> (NYSE:TDOC). Last year, Teladoc generated $1.09 billion in sales. But by 2025, Wall Street's consensus has the company pegged for $4.98 billion in sales.</p>\n<p>There's little question that Teladoc Health benefited immensely from the COVID-19 pandemic. With physicians wanting to keep potentially sick and high-risk people out of their offices, demand for virtual visits soared.</p>\n<p>But this isn't a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-trick pony. What Teladoc is doing is fundamentally altering the personalized treatment landscape. While virtual services won't replace all in-person visits, it's far more convenient for patients, and it can help doctors keep better tabs on chronically ill patients. Ultimately, that's a recipe for improved patient outcomes and less money out of the pockets of health insurers.</p>\n<p>Teladoc also expects a serious long-term growth boost from the acquisition of leading applied health signals company Livongo Health. Livongo leans on artificial intelligence to send tips to its chronic care members to help them lead healthier lives. With a focus on diabetes, hypertension, and weight management, Livongo's services could cater to a large swath of the U.S. adult population.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Fretail-shopping-store-online-sale-smartphone-website-ecommerce-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sea Limited: 430% implied sales growth by 2024</h2>\n<p>Singapore-based <b>Sea Limited</b> (NYSE:SE) is expected to deliver such robust sales growth that it doesn't even need a full five years. With consensus estimates looking out to 2024, the company's sales are projected to more than quintuple to $23.2 billion from $4.38 billion in 2020.</p>\n<p>Sea's success is the result of three very different but rapidly growing segments. The first, digital entertainment, is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea had approximately 725 million quarterly active mobile game users in the June-ended quarter, 12.7% of which were paying customers.&nbsp; For some context, only about 2% of mobile gamers are being converted to paying customers industrywide.</p>\n<p>Second, and arguably the more intriguing segment, is its e-commerce platform Shopee. Shopee has consistently been the most downloaded shopping app in Southeastern Asia, and it managed $15 billion in gross merchandise value (GMV) on its platform in the second quarter. This $60 billion annual run-rate is a 500% increase from what it did in all of 2018 ($10 billion in GMV). E-commerce sales in the emerging market countries Shopee serves are still in the early stages of ramping up.</p>\n<p>Third, Sea's digital financial services segment has almost 33 million paying digital wallet customers. Since many of the markets Sea serves are underbanked, mobile wallets could be a key growth driver for the company.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Fsiblings-watch-tv-family-entertainment-show-network-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Roku: 408% implied sales growth by 2025</h2>\n<p>Television streaming platform <b>Roku</b> (NASDAQ:ROKU) is yet another big-name stock on pace to more than quintuple sales in just five years. After bringing in $1.78 billion in full-year sales in 2020, Wall Street's consensus is calling for about $9.05 billion in revenue by 2025. That's an increase of 408%.</p>\n<p>Roku has two key catalysts in its sails. First, there's ongoing cord-cutting from consumers. Over a four-year stretch, the number of U.S. households with traditional cable, satellite, or telcoTV services has fallen by more than 21 million to 75.6 million, according to a report from NScreenMedia.com. Meanwhile, the number of households without these traditional services now stands at more than 50 million. The opportunity to provide these households with streaming content of their choosing, be it free or paid content, is clearly helping Roku win over customers (55.1 million active accounts, as of June 2021).</p>\n<p>But the more exciting opportunity for Roku is with programmatic digital ads. As consumers shift their viewing content from traditional cable and satellite to streaming providers, advertisers are responding by putting more of their budget to work with companies like Roku. More active accounts will give Roku increased ad pricing power, which in turn will it allow it grow its average revenue per user (ARPU) at a rapid clip. In the June-ended quarter, ARPU grew by 46%, even though active accounts increased by only 28% year over year.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Fcoronavirus-vaccine-doctor-patient-healthcare-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna: 1,605% implied sales growth by 2025</h2>\n<p>However, the king of the mountain, at least on this list, is biotech stock <b>Moderna</b> (NASDAQ:MRNA). Sales for Moderna are expected to grow from a reported $803.4 million in 2020 to an estimated $13.7 billion by 2025. That's an increase of more than 1,600%!</p>\n<p>While it's not uncommon to see rapid nominal sales growth when clinical-stage biotech stocks introduce their first drug for sale, Moderna's launch from minimal revenue to multiple billions occurred quickly, thanks to its development of a COVID-19 vaccine, mRNA-1273. In clinical studies, mRNA-1273 led to a 94% vaccine efficacy and demonstrably helped inoculated patients stay out of the hospital with severe forms of the illness.</p>\n<p>From a business standpoint, Moderna continues to benefit from the need to inoculate billions of people worldwide, as well as the mutability of the SARS-CoV-2 virus that causes COVID-19. The need for booster shots or annual vaccines could give Moderna a source of recurring revenue.</p>\n<p>On the other hand, the vaccine space is growing more crowded, with a number of new entrants expected within the U.S. and globally. Considering that mRNA-1273 is the company's only revenue-generating drug, Moderna's $126 billion market cap can best be described as precarious.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 23:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/15/5-big-name-stocks-increase-sales-356-to-1605/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since the Great Recession ended more than 12 years ago, growth stocks have ruled the roost on Wall Street. A combination of historically low lending rates and ongoing quantitative easing measures from...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/15/5-big-name-stocks-increase-sales-356-to-1605/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","SHOP":"Shopify Inc","TDOC":"Teladoc Health Inc.","SE":"Sea Ltd","ROKU":"Roku Inc"},"source_url":"https://www.fool.com/investing/2021/10/15/5-big-name-stocks-increase-sales-356-to-1605/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175112192","content_text":"Since the Great Recession ended more than 12 years ago, growth stocks have ruled the roost on Wall Street. A combination of historically low lending rates and ongoing quantitative easing measures from the Federal Reserve have rolled out the red carpet for fast-paced companies and given them access to abundant cheap capital.\nYet for some high-growth stocks, their parabolic sales increases are just beginning. Based on analysts' consensus sales estimates, the following five big-name stocks are expected to increase their sales by 356% to as much as 1,605% by 2025.\nImage source: Getty Images.\nShopify: 464% implied sales growth by 2025\nThe first well-known hypergrowth stock that could deliver a jaw-dropping sales increase over the next five years is cloud-based e-commerce platform Shopify (NYSE:SHOP). Following $2.93 billion in full-year sales in 2020, Wall Street is forecasting $16.54 billion in annual sales by mid-decade. That's a 464% increase, for those of you keeping score at home.\nThe beauty of the Shopify operating model is that it finds itself in the right place at the right time. Prior to 2020, businesses were shifting their presence online at a steady pace. But in the wake of the pandemic, businesses of all sizes have come to realize how important it is to have their products available for sale on e-commerce marketplaces. Known best for helping small merchants reach large audiences, Shopify estimates its total addressable market for small businesses is currently $153 billion. Thus, with $2.9 billion in sales last year and the company constantly innovating and introducing new tools, it's just scratching the tip of the iceberg in terms of its potential.\nWhat's more, Shopify is benefiting from its high-margin subscription-based services. Whereas entrepreneurs can take advantage of the company's basic services for $29 a month, it offers its core service to small businesses for $79/mo. to $299/mo., or its Shopify Plus service for $2,000/mo. to larger businesses. This is a company that shouldn't have any issue growing its operating margins over time.\nImage source: Getty Images.\nTeladoc Health: 356% implied sales growth by 2025\nAnother big-name stock on track to produce eye-popping sales growth over the next half-decade is telemedicine kingpin Teladoc Health (NYSE:TDOC). Last year, Teladoc generated $1.09 billion in sales. But by 2025, Wall Street's consensus has the company pegged for $4.98 billion in sales.\nThere's little question that Teladoc Health benefited immensely from the COVID-19 pandemic. With physicians wanting to keep potentially sick and high-risk people out of their offices, demand for virtual visits soared.\nBut this isn't a one-trick pony. What Teladoc is doing is fundamentally altering the personalized treatment landscape. While virtual services won't replace all in-person visits, it's far more convenient for patients, and it can help doctors keep better tabs on chronically ill patients. Ultimately, that's a recipe for improved patient outcomes and less money out of the pockets of health insurers.\nTeladoc also expects a serious long-term growth boost from the acquisition of leading applied health signals company Livongo Health. Livongo leans on artificial intelligence to send tips to its chronic care members to help them lead healthier lives. With a focus on diabetes, hypertension, and weight management, Livongo's services could cater to a large swath of the U.S. adult population.\nImage source: Getty Images.\nSea Limited: 430% implied sales growth by 2024\nSingapore-based Sea Limited (NYSE:SE) is expected to deliver such robust sales growth that it doesn't even need a full five years. With consensus estimates looking out to 2024, the company's sales are projected to more than quintuple to $23.2 billion from $4.38 billion in 2020.\nSea's success is the result of three very different but rapidly growing segments. The first, digital entertainment, is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea had approximately 725 million quarterly active mobile game users in the June-ended quarter, 12.7% of which were paying customers.  For some context, only about 2% of mobile gamers are being converted to paying customers industrywide.\nSecond, and arguably the more intriguing segment, is its e-commerce platform Shopee. Shopee has consistently been the most downloaded shopping app in Southeastern Asia, and it managed $15 billion in gross merchandise value (GMV) on its platform in the second quarter. This $60 billion annual run-rate is a 500% increase from what it did in all of 2018 ($10 billion in GMV). E-commerce sales in the emerging market countries Shopee serves are still in the early stages of ramping up.\nThird, Sea's digital financial services segment has almost 33 million paying digital wallet customers. Since many of the markets Sea serves are underbanked, mobile wallets could be a key growth driver for the company.\nImage source: Getty Images.\nRoku: 408% implied sales growth by 2025\nTelevision streaming platform Roku (NASDAQ:ROKU) is yet another big-name stock on pace to more than quintuple sales in just five years. After bringing in $1.78 billion in full-year sales in 2020, Wall Street's consensus is calling for about $9.05 billion in revenue by 2025. That's an increase of 408%.\nRoku has two key catalysts in its sails. First, there's ongoing cord-cutting from consumers. Over a four-year stretch, the number of U.S. households with traditional cable, satellite, or telcoTV services has fallen by more than 21 million to 75.6 million, according to a report from NScreenMedia.com. Meanwhile, the number of households without these traditional services now stands at more than 50 million. The opportunity to provide these households with streaming content of their choosing, be it free or paid content, is clearly helping Roku win over customers (55.1 million active accounts, as of June 2021).\nBut the more exciting opportunity for Roku is with programmatic digital ads. As consumers shift their viewing content from traditional cable and satellite to streaming providers, advertisers are responding by putting more of their budget to work with companies like Roku. More active accounts will give Roku increased ad pricing power, which in turn will it allow it grow its average revenue per user (ARPU) at a rapid clip. In the June-ended quarter, ARPU grew by 46%, even though active accounts increased by only 28% year over year.\nImage source: Getty Images.\nModerna: 1,605% implied sales growth by 2025\nHowever, the king of the mountain, at least on this list, is biotech stock Moderna (NASDAQ:MRNA). Sales for Moderna are expected to grow from a reported $803.4 million in 2020 to an estimated $13.7 billion by 2025. That's an increase of more than 1,600%!\nWhile it's not uncommon to see rapid nominal sales growth when clinical-stage biotech stocks introduce their first drug for sale, Moderna's launch from minimal revenue to multiple billions occurred quickly, thanks to its development of a COVID-19 vaccine, mRNA-1273. In clinical studies, mRNA-1273 led to a 94% vaccine efficacy and demonstrably helped inoculated patients stay out of the hospital with severe forms of the illness.\nFrom a business standpoint, Moderna continues to benefit from the need to inoculate billions of people worldwide, as well as the mutability of the SARS-CoV-2 virus that causes COVID-19. The need for booster shots or annual vaccines could give Moderna a source of recurring revenue.\nOn the other hand, the vaccine space is growing more crowded, with a number of new entrants expected within the U.S. and globally. Considering that mRNA-1273 is the company's only revenue-generating drug, Moderna's $126 billion market cap can best be described as precarious.","news_type":1,"symbols_score_info":{"MRNA":0.9,"ROKU":0.9,"SE":0.9,"SHOP":0.9,"TDOC":0.9}},"isVote":1,"tweetType":1,"viewCount":499,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":826406446,"gmtCreate":1634044956933,"gmtModify":1634044957334,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"up up like like","listText":"up up like like","text":"up up like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/826406446","repostId":"1125261480","repostType":4,"repost":{"id":"1125261480","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634025975,"share":"https://ttm.financial/m/news/1125261480?lang=&edition=full","pubTime":"2021-10-12 16:06","market":"us","language":"en","title":"Ocugen stock surged another 11% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1125261480","media":"Tiger Newspress","summary":"Ocugen stock surged another 11% in premarket trading.The stock rose more than 8% yesterday.","content":"<p>Ocugen stock surged another 11% in premarket trading.The stock rose more than 8% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb24a3fe49c219d7cca5efc7e75316a\" tg-width=\"849\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock surged another 11% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock surged another 11% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-12 16:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ocugen stock surged another 11% in premarket trading.The stock rose more than 8% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb24a3fe49c219d7cca5efc7e75316a\" tg-width=\"849\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125261480","content_text":"Ocugen stock surged another 11% in premarket trading.The stock rose more than 8% yesterday.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":572,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821947650,"gmtCreate":1633692836984,"gmtModify":1633692837369,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"will this become another CEI,i wish...like like","listText":"will this become another CEI,i wish...like like","text":"will this become another CEI,i wish...like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/821947650","repostId":"1118881509","repostType":4,"repost":{"id":"1118881509","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633680221,"share":"https://ttm.financial/m/news/1118881509?lang=&edition=full","pubTime":"2021-10-08 16:03","market":"us","language":"en","title":"Sundial Growers gained nearly 17% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1118881509","media":"Tiger Newspress","summary":"(Oct 8) Sundial Growers Inc. gained nearly 17% in premarket trading, the company buys Alcanna in C$3","content":"<p>(Oct 8)&nbsp;<b><a href=\"https://laohu8.com/S/SNDL\">Sundial Growers Inc.</a></b> gained nearly 17% in premarket trading,&nbsp;the&nbsp;company buys Alcanna in C$346M all-stock deal.</p>\n<p><img src=\"https://static.tigerbbs.com/bbc0301b5f501f1d7d3629926b2f568b\" tg-width=\"1064\" tg-height=\"576\" referrerpolicy=\"no-referrer\">Alcanna is Canada's largest private liquor retailer, operating 171 locations mostly in Alberta, but its majority-owned subsidiary is Canadian cannabis retailer Nova Cannabis.</p>\n<p>\"Alcanna's value-focused model in liquor retailing has created market stability and we believe that the replication of this playbook in cannabis has strong potential to drive a similar result,\" Sundial CEO Zach George says.</p>\n<p>Seeking Alpha contributor IncomeBent Investments sees Sundial Growers asa speculative buy as the Canadian cannabis industry works out the long-term sector leaders.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sundial Growers gained nearly 17% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSundial Growers gained nearly 17% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-08 16:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct 8)&nbsp;<b><a href=\"https://laohu8.com/S/SNDL\">Sundial Growers Inc.</a></b> gained nearly 17% in premarket trading,&nbsp;the&nbsp;company buys Alcanna in C$346M all-stock deal.</p>\n<p><img src=\"https://static.tigerbbs.com/bbc0301b5f501f1d7d3629926b2f568b\" tg-width=\"1064\" tg-height=\"576\" referrerpolicy=\"no-referrer\">Alcanna is Canada's largest private liquor retailer, operating 171 locations mostly in Alberta, but its majority-owned subsidiary is Canadian cannabis retailer Nova Cannabis.</p>\n<p>\"Alcanna's value-focused model in liquor retailing has created market stability and we believe that the replication of this playbook in cannabis has strong potential to drive a similar result,\" Sundial CEO Zach George says.</p>\n<p>Seeking Alpha contributor IncomeBent Investments sees Sundial Growers asa speculative buy as the Canadian cannabis industry works out the long-term sector leaders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNDL":"SNDL Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118881509","content_text":"(Oct 8) Sundial Growers Inc. gained nearly 17% in premarket trading, the company buys Alcanna in C$346M all-stock deal.\nAlcanna is Canada's largest private liquor retailer, operating 171 locations mostly in Alberta, but its majority-owned subsidiary is Canadian cannabis retailer Nova Cannabis.\n\"Alcanna's value-focused model in liquor retailing has created market stability and we believe that the replication of this playbook in cannabis has strong potential to drive a similar result,\" Sundial CEO Zach George says.\nSeeking Alpha contributor IncomeBent Investments sees Sundial Growers asa speculative buy as the Canadian cannabis industry works out the long-term sector leaders.","news_type":1,"symbols_score_info":{"SNDL":0.9}},"isVote":1,"tweetType":1,"viewCount":659,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865542327,"gmtCreate":1633006759932,"gmtModify":1633006760339,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"sometimes all tis old cos. really must learn from Elon Musk: talk big and do fast than whine sorrow and do slow...jus a small thinker ....like like","listText":"sometimes all tis old cos. really must learn from Elon Musk: talk big and do fast than whine sorrow and do slow...jus a small thinker ....like like","text":"sometimes all tis old cos. really must learn from Elon Musk: talk big and do fast than whine sorrow and do slow...jus a small thinker ....like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/865542327","repostId":"1194706585","repostType":2,"isVote":1,"tweetType":1,"viewCount":1073,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":0,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"content":"Yes Elon Musk is bigger than life👍😊","text":"Yes Elon Musk is bigger than life👍😊","html":"Yes Elon Musk is bigger than life👍😊"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865541223,"gmtCreate":1633006470779,"gmtModify":1633006471159,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Nio to the multiverse moons yeah...","listText":"Nio to the multiverse moons yeah...","text":"Nio to the multiverse moons yeah...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/865541223","repostId":"1152595089","repostType":2,"isVote":1,"tweetType":1,"viewCount":734,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":0,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"content":"Nio to the moon 👍😊🚀🚀🚀🌛🌛🌛","text":"Nio to the moon 👍😊🚀🚀🚀🌛🌛🌛","html":"Nio to the moon 👍😊🚀🚀🚀🌛🌛🌛"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865086106,"gmtCreate":1632924013140,"gmtModify":1632924057158,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"EVery EV Evolute EVeryone&nbsp;EVentually.[财迷]&nbsp;&nbsp;","listText":"EVery EV Evolute EVeryone&nbsp;EVentually.[财迷]&nbsp;&nbsp;","text":"EVery EV Evolute EVeryone EVentually.[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/865086106","repostId":"1120133380","repostType":4,"repost":{"id":"1120133380","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632923519,"share":"https://ttm.financial/m/news/1120133380?lang=&edition=full","pubTime":"2021-09-29 21:51","market":"us","language":"en","title":"Some hot EV stocks rallied in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1120133380","media":"Tiger Newspress","summary":"Some hot EV stocks rallied in morning trading.Tesla,Nio,Xpeng Motors, Li Auto,Lucid,Nikola and Lords","content":"<p>Some hot EV stocks rallied in morning trading.Tesla,Nio,Xpeng Motors, Li Auto,Lucid,Nikola&nbsp;and&nbsp;Lordstown&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/9c1e1472c9d7e5d7c5b97601195415ed\" tg-width=\"403\" tg-height=\"422\" referrerpolicy=\"no-referrer\"></p>\n<p>Wedbush expects Tesla&nbsp;have&nbsp;a&nbsp;strong 3Q deliveries on accelerating EV demand, Musk and Co could deliver 150k vehicles in September alone.</p>\n<p>U.S. startup Lucid Group Inc&nbsp;said on Tuesday it will start delivering luxury electric sedans with a Tesla-beating driving range in late October.</p>\n<p>Lucid Group is on track to meet its production targets for 2022 and 2023 and is pushing to achieve this year's goal of 577 vehicles, its chief executive said.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some hot EV stocks rallied in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome hot EV stocks rallied in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-29 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some hot EV stocks rallied in morning trading.Tesla,Nio,Xpeng Motors, Li Auto,Lucid,Nikola&nbsp;and&nbsp;Lordstown&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/9c1e1472c9d7e5d7c5b97601195415ed\" tg-width=\"403\" tg-height=\"422\" referrerpolicy=\"no-referrer\"></p>\n<p>Wedbush expects Tesla&nbsp;have&nbsp;a&nbsp;strong 3Q deliveries on accelerating EV demand, Musk and Co could deliver 150k vehicles in September alone.</p>\n<p>U.S. startup Lucid Group Inc&nbsp;said on Tuesday it will start delivering luxury electric sedans with a Tesla-beating driving range in late October.</p>\n<p>Lucid Group is on track to meet its production targets for 2022 and 2023 and is pushing to achieve this year's goal of 577 vehicles, its chief executive said.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉","LCID":"Lucid Group Inc","XPEV":"小鹏汽车","LI":"理想汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120133380","content_text":"Some hot EV stocks rallied in morning trading.Tesla,Nio,Xpeng Motors, Li Auto,Lucid,Nikola and Lordstown climbed between 1% and 13%.\n\nWedbush expects Tesla have a strong 3Q deliveries on accelerating EV demand, Musk and Co could deliver 150k vehicles in September alone.\nU.S. startup Lucid Group Inc said on Tuesday it will start delivering luxury electric sedans with a Tesla-beating driving range in late October.\nLucid Group is on track to meet its production targets for 2022 and 2023 and is pushing to achieve this year's goal of 577 vehicles, its chief executive said.","news_type":1,"symbols_score_info":{"LCID":0.9,"LI":0.9,"NIO":0.9,"TSLA":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":703,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866535091,"gmtCreate":1632789678113,"gmtModify":1632797585127,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"reaching $15 aiming $16","listText":"reaching $15 aiming $16","text":"reaching $15 aiming $16","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/866535091","repostId":"866882541","repostType":1,"repost":{"id":866882541,"gmtCreate":1632753456483,"gmtModify":1632798074429,"author":{"id":"3568875902358937","authorId":"3568875902358937","name":"Zonnnggg","avatar":"https://static.tigerbbs.com/7f416adefcc55425b663626cd3a51516","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568875902358937","authorIdStr":"3568875902358937"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/F\">$Ford(F)$</a>More?","listText":"<a href=\"https://laohu8.com/S/F\">$Ford(F)$</a>More?","text":"$Ford(F)$More?","images":[{"img":"https://static.tigerbbs.com/c187127792b60597e3826d77bcc0c479","width":"1284","height":"2778"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/866882541","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":859,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":863228838,"gmtCreate":1632400543624,"gmtModify":1632800680454,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Nio niu (bull)ah!","listText":"Nio niu (bull)ah!","text":"Nio niu (bull)ah!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/863228838","repostId":"1135139549","repostType":4,"repost":{"id":"1135139549","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1632386313,"share":"https://ttm.financial/m/news/1135139549?lang=&edition=full","pubTime":"2021-09-23 16:38","market":"us","language":"en","title":"Nio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1135139549","media":"Benzinga","summary":"Chinese electric vehicle maker NIO Inc. is delaying the official launch of the ES8 SUV and the openi","content":"<p>Chinese electric vehicle maker&nbsp;<b><a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a></b> is delaying the official launch of the ES8 SUV and the opening of the first overseas&nbsp;<b>Nio House</b>&nbsp;in Norway by a week, cnEVpostreportedWednesday.</p>\n<p><b>What Happened</b>: Nio will now launch the ES8 in Norway on Sept. 30 while the first local Nio House in Oslo will be officially open for business from Oct. 1, as per the report that&nbsp;<b>Marius Hayler</b>, general manager of Nio Norway.</p>\n<p>The report did not provide any details about the reasons for the delay. It was&nbsp;reported&nbsp;earlier this month the EV maker will open the Nio House in Norway and also announce the local pricing of its flagship ES8 model on Sept. 23.</p>\n<p>Nio House is the EV maker’s concept store.</p>\n<p><b>Why It Matters</b>: &nbsp;Nio’s entry into Norway marks the first step in an ambitious overseas expansion plan charted by the EV maker, which has found success in <a href=\"https://laohu8.com/S/CAAS\">China</a> as a seller of premium electric vehicles.</p>\n<p>NIO CEO<b>Wiliam Li</b>has said that the company may expand into Germany, followed by other European countries, if it achieves success in Norway.</p>\n<p><b>Price Action</b>: Nio shares closed almost 2.3% higher in Wednesday’s trading at $35.70.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-09-23 16:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chinese electric vehicle maker&nbsp;<b><a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a></b> is delaying the official launch of the ES8 SUV and the opening of the first overseas&nbsp;<b>Nio House</b>&nbsp;in Norway by a week, cnEVpostreportedWednesday.</p>\n<p><b>What Happened</b>: Nio will now launch the ES8 in Norway on Sept. 30 while the first local Nio House in Oslo will be officially open for business from Oct. 1, as per the report that&nbsp;<b>Marius Hayler</b>, general manager of Nio Norway.</p>\n<p>The report did not provide any details about the reasons for the delay. It was&nbsp;reported&nbsp;earlier this month the EV maker will open the Nio House in Norway and also announce the local pricing of its flagship ES8 model on Sept. 23.</p>\n<p>Nio House is the EV maker’s concept store.</p>\n<p><b>Why It Matters</b>: &nbsp;Nio’s entry into Norway marks the first step in an ambitious overseas expansion plan charted by the EV maker, which has found success in <a href=\"https://laohu8.com/S/CAAS\">China</a> as a seller of premium electric vehicles.</p>\n<p>NIO CEO<b>Wiliam Li</b>has said that the company may expand into Germany, followed by other European countries, if it achieves success in Norway.</p>\n<p><b>Price Action</b>: Nio shares closed almost 2.3% higher in Wednesday’s trading at $35.70.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135139549","content_text":"Chinese electric vehicle maker NIO Inc. is delaying the official launch of the ES8 SUV and the opening of the first overseas Nio House in Norway by a week, cnEVpostreportedWednesday.\nWhat Happened: Nio will now launch the ES8 in Norway on Sept. 30 while the first local Nio House in Oslo will be officially open for business from Oct. 1, as per the report that Marius Hayler, general manager of Nio Norway.\nThe report did not provide any details about the reasons for the delay. It was reported earlier this month the EV maker will open the Nio House in Norway and also announce the local pricing of its flagship ES8 model on Sept. 23.\nNio House is the EV maker’s concept store.\nWhy It Matters:  Nio’s entry into Norway marks the first step in an ambitious overseas expansion plan charted by the EV maker, which has found success in China as a seller of premium electric vehicles.\nNIO CEOWiliam Lihas said that the company may expand into Germany, followed by other European countries, if it achieves success in Norway.\nPrice Action: Nio shares closed almost 2.3% higher in Wednesday’s trading at $35.70.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":819412201,"gmtCreate":1630086512203,"gmtModify":1704955819113,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"when bitcoin rise back to $60k????","listText":"when bitcoin rise back to $60k????","text":"when bitcoin rise back to $60k????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/819412201","repostId":"1199074003","repostType":4,"repost":{"id":"1199074003","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630077382,"share":"https://ttm.financial/m/news/1199074003?lang=&edition=full","pubTime":"2021-08-27 23:16","market":"us","language":"en","title":"Crypto stocks surged in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1199074003","media":"Tiger Newspress","summary":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,","content":"<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks surged in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks surged in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-27 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SOS":"SOS Limited","RIOT":"Riot Platforms","BTCM":"BIT Mining","CAN":"嘉楠科技","MARA":"MARA Holdings","EBON":"亿邦国际","NCTY":"第九城市","BTBT":"Bit Digital, Inc.","COIN":"Coinbase Global, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199074003","content_text":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase and Paypal climbed between 1% and 13%.","news_type":1,"symbols_score_info":{"BTBT":0.9,"BTCM":0.9,"CAN":0.9,"COIN":0.9,"EBON":0.9,"MARA":0.9,"NCTY":0.9,"RIOT":0.9,"SOS":0.9,"SQ":0.9}},"isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":865541223,"gmtCreate":1633006470779,"gmtModify":1633006471159,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Nio to the multiverse moons yeah...","listText":"Nio to the multiverse moons yeah...","text":"Nio to the multiverse moons yeah...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/865541223","repostId":"1152595089","repostType":2,"isVote":1,"tweetType":1,"viewCount":734,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":0,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"content":"Nio to the moon 👍😊🚀🚀🚀🌛🌛🌛","text":"Nio to the moon 👍😊🚀🚀🚀🌛🌛🌛","html":"Nio to the moon 👍😊🚀🚀🚀🌛🌛🌛"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":886746757,"gmtCreate":1631628084679,"gmtModify":1631886507380,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"still dun understand about hype on Nikola[疑问]&nbsp;","listText":"still dun understand about hype on Nikola[疑问]&nbsp;","text":"still dun understand about hype on Nikola[疑问]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/886746757","repostId":"1155175288","repostType":4,"repost":{"id":"1155175288","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631627144,"share":"https://ttm.financial/m/news/1155175288?lang=&edition=full","pubTime":"2021-09-14 21:45","market":"us","language":"en","title":"EV stocks rose in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1155175288","media":"Tiger Newspress","summary":"EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto climbed between 0.7% and 2%.Whi","content":"<p>EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto&nbsp;climbed between 0.7% and 2%.While&nbsp;Lucid Group fell nearly 4%&nbsp;as&nbsp;an equity research analyst at Morgan Stanley initiated coverage of the company at underweight.</p>\n<p><img src=\"https://static.tigerbbs.com/df9a72b93885e07dad67e2dc86b0156a\" tg-width=\"410\" tg-height=\"483\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks rose in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks rose in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-14 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto&nbsp;climbed between 0.7% and 2%.While&nbsp;Lucid Group fell nearly 4%&nbsp;as&nbsp;an equity research analyst at Morgan Stanley initiated coverage of the company at underweight.</p>\n<p><img src=\"https://static.tigerbbs.com/df9a72b93885e07dad67e2dc86b0156a\" tg-width=\"410\" tg-height=\"483\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉","XPEV":"小鹏汽车","LI":"理想汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155175288","content_text":"EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto climbed between 0.7% and 2%.While Lucid Group fell nearly 4% as an equity research analyst at Morgan Stanley initiated coverage of the company at underweight.","news_type":1,"symbols_score_info":{"LI":0.9,"NIO":0.9,"TSLA":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":886336965,"gmtCreate":1631549461457,"gmtModify":1631886507393,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"ford should be a $15 share..i wish","listText":"ford should be a $15 share..i wish","text":"ford should be a $15 share..i wish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/886336965","repostId":"2167658404","repostType":2,"isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814358162,"gmtCreate":1630768928456,"gmtModify":1631886507448,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>hope to reach half Tesla price haha","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>hope to reach half Tesla price haha","text":"$NIO Inc.(NIO)$hope to reach half Tesla price haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/814358162","isVote":1,"tweetType":1,"viewCount":749,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":879786388,"gmtCreate":1636773154807,"gmtModify":1636773154970,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Pfizer the old giant ,time to wake upupup...i wish...like like","listText":"Pfizer the old giant ,time to wake upupup...i wish...like like","text":"Pfizer the old giant ,time to wake upupup...i wish...like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/879786388","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://ttm.financial/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":863229400,"gmtCreate":1632400374400,"gmtModify":1632800683129,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Pfizer can reach $50 by Oct....i wish","listText":"Pfizer can reach $50 by Oct....i wish","text":"Pfizer can reach $50 by Oct....i wish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/863229400","repostId":"1133566174","repostType":4,"isVote":1,"tweetType":1,"viewCount":305,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869784588,"gmtCreate":1632322282944,"gmtModify":1632801226942,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Maybe&nbsp;Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","listText":"Maybe&nbsp;Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","text":"Maybe Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/869784588","repostId":"1143821004","repostType":4,"isVote":1,"tweetType":1,"viewCount":433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819418625,"gmtCreate":1630086116667,"gmtModify":1704955816003,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"when nio xpeng rise to$50???","listText":"when nio xpeng rise to$50???","text":"when nio xpeng rise to$50???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/819418625","repostId":"2162021329","repostType":4,"repost":{"id":"2162021329","kind":"highlight","pubTimestamp":1630076362,"share":"https://ttm.financial/m/news/2162021329?lang=&edition=full","pubTime":"2021-08-27 22:59","market":"us","language":"en","title":"Why Lordstown Motors Stock Has Surged This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2162021329","media":"Motley Fool","summary":"And why investors should temper their enthusiasm.","content":"<h2>What happened</h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/RIDE\">Lordstown Motors Corp.</a> </b>(NASDAQ:RIDE) surged 24.1% this week through Thursday, following news that the embattled electric truck start-up has hired a new CEO with deep auto industry experience.</p>\n<p>That's encouraging news for investors who have watched the stock decline sharply in recent months. But while the new CEO has a solid resume, the company faces a daunting road to delivering on investors' expectations.</p>\n<h2>So what</h2>\n<p>Lordstown said on Thursday that it has a new CEO: Daniel Ninivaggi is the former CEO of investor Carl Icahn's automotive holdings, and earlier held executive roles at Tier 1 auto suppliers <b>Lear</b>&nbsp;and Federal Mogul (now part of <b>Tenneco</b>).&nbsp;</p>\n<p>Ninivaggi will need all his experience to get Lordstown on track. The company has been reeling since the abrupt departure of its founder and its chief financial officer in June, following an investigation into allegations that they greatly exaggerated customer interest in Lordstown's upcoming electric Endurance pickup.&nbsp;</p>\n<p>Now, Lordstown is short on cash and short on potential sources of new cash, just as it appears to have lost its first-mover advantage to commercial-vehicle market leader <b>Ford Motor Company</b>. (Investors hoping that Ninivaggi might bring a big investment from Icahn should note Ninivaggi parted ways with Icahn's organization in 2019.)&nbsp;</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F640972%2Flordstown-endurance-pickup-1.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Lordstown's truck is behind schedule and buyers don't appear to be lining up. Can new CEO Ninivaggi turn things around? Image source: Lordstown Motors.</p>\n<p>But that said, the arrival of Ninivaggi is good news, and I think investors were right to be cheered this week.</p>\n<h2>Now what</h2>\n<p>Ninivaggi can almost certainly help address Lordstown's urgent needs right away, at least to some extent. His resume brings the kind of credibility that can open doors with potential investors and other automotive heavyweights.&nbsp;</p>\n<p>But investors shouldn't underestimate the difficulties here, even with Ninivaggi steering the shop. Simply put, Lordstown needs to be able to establish a beachhead in the super competitive commercial vehicle market to survive -- and now that giant Ford has thrown down a gauntlet with its impressive F-150 Lightning, that will be a big, big challenge.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Lordstown Motors Stock Has Surged This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Lordstown Motors Stock Has Surged This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 22:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/27/why-lordstown-motors-stock-has-surged-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Lordstown Motors Corp. (NASDAQ:RIDE) surged 24.1% this week through Thursday, following news that the embattled electric truck start-up has hired a new CEO with deep auto ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/27/why-lordstown-motors-stock-has-surged-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/08/27/why-lordstown-motors-stock-has-surged-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162021329","content_text":"What happened\nShares of Lordstown Motors Corp. (NASDAQ:RIDE) surged 24.1% this week through Thursday, following news that the embattled electric truck start-up has hired a new CEO with deep auto industry experience.\nThat's encouraging news for investors who have watched the stock decline sharply in recent months. But while the new CEO has a solid resume, the company faces a daunting road to delivering on investors' expectations.\nSo what\nLordstown said on Thursday that it has a new CEO: Daniel Ninivaggi is the former CEO of investor Carl Icahn's automotive holdings, and earlier held executive roles at Tier 1 auto suppliers Lear and Federal Mogul (now part of Tenneco). \nNinivaggi will need all his experience to get Lordstown on track. The company has been reeling since the abrupt departure of its founder and its chief financial officer in June, following an investigation into allegations that they greatly exaggerated customer interest in Lordstown's upcoming electric Endurance pickup. \nNow, Lordstown is short on cash and short on potential sources of new cash, just as it appears to have lost its first-mover advantage to commercial-vehicle market leader Ford Motor Company. (Investors hoping that Ninivaggi might bring a big investment from Icahn should note Ninivaggi parted ways with Icahn's organization in 2019.) \n\nLordstown's truck is behind schedule and buyers don't appear to be lining up. Can new CEO Ninivaggi turn things around? Image source: Lordstown Motors.\nBut that said, the arrival of Ninivaggi is good news, and I think investors were right to be cheered this week.\nNow what\nNinivaggi can almost certainly help address Lordstown's urgent needs right away, at least to some extent. His resume brings the kind of credibility that can open doors with potential investors and other automotive heavyweights. \nBut investors shouldn't underestimate the difficulties here, even with Ninivaggi steering the shop. Simply put, Lordstown needs to be able to establish a beachhead in the super competitive commercial vehicle market to survive -- and now that giant Ford has thrown down a gauntlet with its impressive F-150 Lightning, that will be a big, big challenge.","news_type":1,"symbols_score_info":{"RIDE":0.9}},"isVote":1,"tweetType":1,"viewCount":477,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":605437594,"gmtCreate":1639212100832,"gmtModify":1639212101161,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"calm before the tsunami...i wish...like like","listText":"calm before the tsunami...i wish...like like","text":"calm before the tsunami...i wish...like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605437594","repostId":"1133027099","repostType":4,"repost":{"id":"1133027099","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639152670,"share":"https://ttm.financial/m/news/1133027099?lang=&edition=full","pubTime":"2021-12-11 00:11","market":"us","language":"en","title":"Sea Ltd stock dropped more than 5% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133027099","media":"Tiger Newspress","summary":"Sea Ltd stock dropped more than 5% in morning trading.","content":"<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Ltd stock dropped more than 5% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Ltd stock dropped more than 5% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-11 00:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133027099","content_text":"Sea Ltd stock dropped more than 5% in morning trading.","news_type":1,"symbols_score_info":{"SE":0.9}},"isVote":1,"tweetType":1,"viewCount":2012,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859459142,"gmtCreate":1634724598127,"gmtModify":1634724733333,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"nio niu (bullish) yah... like like","listText":"nio niu (bullish) yah... like like","text":"nio niu (bullish) yah... like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/859459142","repostId":"2176832734","repostType":4,"repost":{"id":"2176832734","kind":"news","pubTimestamp":1634721059,"share":"https://ttm.financial/m/news/2176832734?lang=&edition=full","pubTime":"2021-10-20 17:10","market":"us","language":"en","title":"NIO May Bring ET7's Electric Drive System To All Models: Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2176832734","media":"Benzinga","summary":"Chinese electric vehicle maker Nio Inc (NYSE: NIO) may introduce its electric sedan ET7’s electric d","content":"<p><img src=\"https://static.tigerbbs.com/747ca2d6065a7a14c35dbba18ac30ac6\" tg-width=\"600\" tg-height=\"400\" referrerpolicy=\"no-referrer\"></p>\n<p>Chinese electric vehicle maker <b>Nio Inc</b> (NYSE: NIO) may introduce its electric sedan ET7’s electric drive system to all models, cnEVpost reported on Tuesday, citing a Chinese news publication.</p>\n<p><b>What Happened: </b>The Shanghai-headquartered Nio may bring the second-generation electric motor to other models such as the ES8, ES6 and EC6, as per reports coming from China.</p>\n<p>The electric drive system has a combined system power of 480kW — 180kW at the front and 300kW at the rear — and a peak torque of 850 Nm.</p>\n<p><i>See Also: Nio Prices ES8 SUV Lower In Norway Than Home Country China, Unveils Nio House In Oslo</i></p>\n<p><b>Why It Matters:</b>&nbsp;Nio, founded in 2014,&nbsp;launched the flagship sedan ET7 in January at the company’s annual day, complete with its second-generation electric drive system.</p>\n<p>This system utilizes&nbsp;<b>silicon carbide (SiC),</b>&nbsp;which is considered more efficient, lightweight and compact than silicon. Rival&nbsp;<b>Tesla Inc</b> (NASDAQ: TSLA)&nbsp;was the first to use SiC of all peers, putting chips made of the world's third-hardest substance in inverters of some Model 3 vehicles, Nikkei Asia reported last month.</p>\n<p>Nio is among a growing breed of homegrown Chinese electric vehicle startups beside&nbsp;<b>Xpeng Inc</b> (NYSE: XPEV) and&nbsp;<b>Li Auto Inc&nbsp;</b>(NASDAQ: LI),&nbsp;which have quickly established themselves locally with their all-electric lineup&nbsp;and are now eyeing international expansion.</p>\n<p>In May, the electric vehicle maker revealed plans to expand to markets outside of China, starting with Norway.</p>\n<p><b>Price Action:</b> Nio shares closed 1.06% higher at $40.03 a share on Tuesday.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NIO May Bring ET7's Electric Drive System To All Models: Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNIO May Bring ET7's Electric Drive System To All Models: Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-20 17:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/nio-may-bring-et7s-electric-024359218.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese electric vehicle maker Nio Inc (NYSE: NIO) may introduce its electric sedan ET7’s electric drive system to all models, cnEVpost reported on Tuesday, citing a Chinese news publication.\nWhat ...</p>\n\n<a href=\"https://finance.yahoo.com/news/nio-may-bring-et7s-electric-024359218.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://finance.yahoo.com/news/nio-may-bring-et7s-electric-024359218.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2176832734","content_text":"Chinese electric vehicle maker Nio Inc (NYSE: NIO) may introduce its electric sedan ET7’s electric drive system to all models, cnEVpost reported on Tuesday, citing a Chinese news publication.\nWhat Happened: The Shanghai-headquartered Nio may bring the second-generation electric motor to other models such as the ES8, ES6 and EC6, as per reports coming from China.\nThe electric drive system has a combined system power of 480kW — 180kW at the front and 300kW at the rear — and a peak torque of 850 Nm.\nSee Also: Nio Prices ES8 SUV Lower In Norway Than Home Country China, Unveils Nio House In Oslo\nWhy It Matters: Nio, founded in 2014, launched the flagship sedan ET7 in January at the company’s annual day, complete with its second-generation electric drive system.\nThis system utilizes silicon carbide (SiC), which is considered more efficient, lightweight and compact than silicon. Rival Tesla Inc (NASDAQ: TSLA) was the first to use SiC of all peers, putting chips made of the world's third-hardest substance in inverters of some Model 3 vehicles, Nikkei Asia reported last month.\nNio is among a growing breed of homegrown Chinese electric vehicle startups beside Xpeng Inc (NYSE: XPEV) and Li Auto Inc (NASDAQ: LI), which have quickly established themselves locally with their all-electric lineup and are now eyeing international expansion.\nIn May, the electric vehicle maker revealed plans to expand to markets outside of China, starting with Norway.\nPrice Action: Nio shares closed 1.06% higher at $40.03 a share on Tuesday.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":2186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865542327,"gmtCreate":1633006759932,"gmtModify":1633006760339,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"sometimes all tis old cos. really must learn from Elon Musk: talk big and do fast than whine sorrow and do slow...jus a small thinker ....like like","listText":"sometimes all tis old cos. really must learn from Elon Musk: talk big and do fast than whine sorrow and do slow...jus a small thinker ....like like","text":"sometimes all tis old cos. really must learn from Elon Musk: talk big and do fast than whine sorrow and do slow...jus a small thinker ....like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/865542327","repostId":"1194706585","repostType":2,"isVote":1,"tweetType":1,"viewCount":1073,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":0,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"content":"Yes Elon Musk is bigger than life👍😊","text":"Yes Elon Musk is bigger than life👍😊","html":"Yes Elon Musk is bigger than life👍😊"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":818294685,"gmtCreate":1630411172447,"gmtModify":1631883652234,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Alibaba or Sea Ltd reach $500 first??","listText":"Alibaba or Sea Ltd reach $500 first??","text":"Alibaba or Sea Ltd reach $500 first??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/818294685","repostId":"2163859671","repostType":4,"isVote":1,"tweetType":1,"viewCount":607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":865086106,"gmtCreate":1632924013140,"gmtModify":1632924057158,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"EVery EV Evolute EVeryone&nbsp;EVentually.[财迷]&nbsp;&nbsp;","listText":"EVery EV Evolute EVeryone&nbsp;EVentually.[财迷]&nbsp;&nbsp;","text":"EVery EV Evolute EVeryone EVentually.[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/865086106","repostId":"1120133380","repostType":4,"repost":{"id":"1120133380","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632923519,"share":"https://ttm.financial/m/news/1120133380?lang=&edition=full","pubTime":"2021-09-29 21:51","market":"us","language":"en","title":"Some hot EV stocks rallied in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1120133380","media":"Tiger Newspress","summary":"Some hot EV stocks rallied in morning trading.Tesla,Nio,Xpeng Motors, Li Auto,Lucid,Nikola and Lords","content":"<p>Some hot EV stocks rallied in morning trading.Tesla,Nio,Xpeng Motors, Li Auto,Lucid,Nikola&nbsp;and&nbsp;Lordstown&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/9c1e1472c9d7e5d7c5b97601195415ed\" tg-width=\"403\" tg-height=\"422\" referrerpolicy=\"no-referrer\"></p>\n<p>Wedbush expects Tesla&nbsp;have&nbsp;a&nbsp;strong 3Q deliveries on accelerating EV demand, Musk and Co could deliver 150k vehicles in September alone.</p>\n<p>U.S. startup Lucid Group Inc&nbsp;said on Tuesday it will start delivering luxury electric sedans with a Tesla-beating driving range in late October.</p>\n<p>Lucid Group is on track to meet its production targets for 2022 and 2023 and is pushing to achieve this year's goal of 577 vehicles, its chief executive said.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some hot EV stocks rallied in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome hot EV stocks rallied in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-29 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some hot EV stocks rallied in morning trading.Tesla,Nio,Xpeng Motors, Li Auto,Lucid,Nikola&nbsp;and&nbsp;Lordstown&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/9c1e1472c9d7e5d7c5b97601195415ed\" tg-width=\"403\" tg-height=\"422\" referrerpolicy=\"no-referrer\"></p>\n<p>Wedbush expects Tesla&nbsp;have&nbsp;a&nbsp;strong 3Q deliveries on accelerating EV demand, Musk and Co could deliver 150k vehicles in September alone.</p>\n<p>U.S. startup Lucid Group Inc&nbsp;said on Tuesday it will start delivering luxury electric sedans with a Tesla-beating driving range in late October.</p>\n<p>Lucid Group is on track to meet its production targets for 2022 and 2023 and is pushing to achieve this year's goal of 577 vehicles, its chief executive said.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉","LCID":"Lucid Group Inc","XPEV":"小鹏汽车","LI":"理想汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120133380","content_text":"Some hot EV stocks rallied in morning trading.Tesla,Nio,Xpeng Motors, Li Auto,Lucid,Nikola and Lordstown climbed between 1% and 13%.\n\nWedbush expects Tesla have a strong 3Q deliveries on accelerating EV demand, Musk and Co could deliver 150k vehicles in September alone.\nU.S. startup Lucid Group Inc said on Tuesday it will start delivering luxury electric sedans with a Tesla-beating driving range in late October.\nLucid Group is on track to meet its production targets for 2022 and 2023 and is pushing to achieve this year's goal of 577 vehicles, its chief executive said.","news_type":1,"symbols_score_info":{"LCID":0.9,"LI":0.9,"NIO":0.9,"TSLA":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":703,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":863228838,"gmtCreate":1632400543624,"gmtModify":1632800680454,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Nio niu (bull)ah!","listText":"Nio niu (bull)ah!","text":"Nio niu (bull)ah!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/863228838","repostId":"1135139549","repostType":4,"repost":{"id":"1135139549","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1632386313,"share":"https://ttm.financial/m/news/1135139549?lang=&edition=full","pubTime":"2021-09-23 16:38","market":"us","language":"en","title":"Nio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1135139549","media":"Benzinga","summary":"Chinese electric vehicle maker NIO Inc. is delaying the official launch of the ES8 SUV and the openi","content":"<p>Chinese electric vehicle maker&nbsp;<b><a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a></b> is delaying the official launch of the ES8 SUV and the opening of the first overseas&nbsp;<b>Nio House</b>&nbsp;in Norway by a week, cnEVpostreportedWednesday.</p>\n<p><b>What Happened</b>: Nio will now launch the ES8 in Norway on Sept. 30 while the first local Nio House in Oslo will be officially open for business from Oct. 1, as per the report that&nbsp;<b>Marius Hayler</b>, general manager of Nio Norway.</p>\n<p>The report did not provide any details about the reasons for the delay. It was&nbsp;reported&nbsp;earlier this month the EV maker will open the Nio House in Norway and also announce the local pricing of its flagship ES8 model on Sept. 23.</p>\n<p>Nio House is the EV maker’s concept store.</p>\n<p><b>Why It Matters</b>: &nbsp;Nio’s entry into Norway marks the first step in an ambitious overseas expansion plan charted by the EV maker, which has found success in <a href=\"https://laohu8.com/S/CAAS\">China</a> as a seller of premium electric vehicles.</p>\n<p>NIO CEO<b>Wiliam Li</b>has said that the company may expand into Germany, followed by other European countries, if it achieves success in Norway.</p>\n<p><b>Price Action</b>: Nio shares closed almost 2.3% higher in Wednesday’s trading at $35.70.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-09-23 16:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chinese electric vehicle maker&nbsp;<b><a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a></b> is delaying the official launch of the ES8 SUV and the opening of the first overseas&nbsp;<b>Nio House</b>&nbsp;in Norway by a week, cnEVpostreportedWednesday.</p>\n<p><b>What Happened</b>: Nio will now launch the ES8 in Norway on Sept. 30 while the first local Nio House in Oslo will be officially open for business from Oct. 1, as per the report that&nbsp;<b>Marius Hayler</b>, general manager of Nio Norway.</p>\n<p>The report did not provide any details about the reasons for the delay. It was&nbsp;reported&nbsp;earlier this month the EV maker will open the Nio House in Norway and also announce the local pricing of its flagship ES8 model on Sept. 23.</p>\n<p>Nio House is the EV maker’s concept store.</p>\n<p><b>Why It Matters</b>: &nbsp;Nio’s entry into Norway marks the first step in an ambitious overseas expansion plan charted by the EV maker, which has found success in <a href=\"https://laohu8.com/S/CAAS\">China</a> as a seller of premium electric vehicles.</p>\n<p>NIO CEO<b>Wiliam Li</b>has said that the company may expand into Germany, followed by other European countries, if it achieves success in Norway.</p>\n<p><b>Price Action</b>: Nio shares closed almost 2.3% higher in Wednesday’s trading at $35.70.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135139549","content_text":"Chinese electric vehicle maker NIO Inc. is delaying the official launch of the ES8 SUV and the opening of the first overseas Nio House in Norway by a week, cnEVpostreportedWednesday.\nWhat Happened: Nio will now launch the ES8 in Norway on Sept. 30 while the first local Nio House in Oslo will be officially open for business from Oct. 1, as per the report that Marius Hayler, general manager of Nio Norway.\nThe report did not provide any details about the reasons for the delay. It was reported earlier this month the EV maker will open the Nio House in Norway and also announce the local pricing of its flagship ES8 model on Sept. 23.\nNio House is the EV maker’s concept store.\nWhy It Matters:  Nio’s entry into Norway marks the first step in an ambitious overseas expansion plan charted by the EV maker, which has found success in China as a seller of premium electric vehicles.\nNIO CEOWiliam Lihas said that the company may expand into Germany, followed by other European countries, if it achieves success in Norway.\nPrice Action: Nio shares closed almost 2.3% higher in Wednesday’s trading at $35.70.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883910341,"gmtCreate":1631195704183,"gmtModify":1631886507432,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"this year buy sea wave&nbsp;for next year sea tusnami[疑问]&nbsp;","listText":"this year buy sea wave&nbsp;for next year sea tusnami[疑问]&nbsp;","text":"this year buy sea wave for next year sea tusnami[疑问]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/883910341","repostId":"1109486521","repostType":4,"repost":{"id":"1109486521","kind":"news","pubTimestamp":1631172960,"share":"https://ttm.financial/m/news/1109486521?lang=&edition=full","pubTime":"2021-09-09 15:36","market":"us","language":"en","title":"Tencent-Backed Tech Giant Sea Taps Investors for About $6 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1109486521","media":"The Wall Street Journal","summary":"(Update: Sept 9, 2021 at 09:44 a.m. ET)\n\nSea says some of the proceeds would help expand its busines","content":"<p><i><b>(Update: Sept 9, 2021 at 09:44 a.m. ET)</b></i></p>\n<blockquote>\n <b>Sea says some of the proceeds would help expand its business, while funds could also be deployed on investments and acquisitions.</b>\n</blockquote>\n<p>Southeast Asia’s most valuable listed company, Sea Ltd., plans to raise about $6 billion or more in new funds, capitalizing on investor enthusiasm for the region’s fast-growing technology industry.</p>\n<p>TheTencent HoldingsLtd.TCEHY-2.95%-backed gaming, e-commerce and digital-finance company said in a filing late Wednesday that it would raise the capital by selling new shares and convertible bonds. Sea said some of the proceeds would help expand its business, while funds could also be deployed on “potential strategic investments and acquisitions.”</p>\n<p>The company says its Shopee unit, which competes with rivals including Alibaba Group Holding Ltd.’s Lazada unit, is the largest e-commerce platform in Southeast Asia and Taiwan.</p>\n<p>Sea, which is listed on the New York Stock Exchange, plans to sell 11 million American depositary shares and $2.5 billion of five-year convertible bonds.</p>\n<p><img src=\"https://static.tigerbbs.com/d09e89c4e1333b681b0605608cff2a6c\" tg-width=\"336\" tg-height=\"424\" referrerpolicy=\"no-referrer\"></p>\n<p>Based on Wednesday’s closing price for Sea shares, of $343.80, the stock sale would be worth close to $3.8 billion, although deals like this are typically sold at a discount to the market price. Sea and its banks expect the final price to be set Thursday, according to a term sheet seen by The Wall Street Journal. The deal’s underwriters have the option to increase the size of both offerings by 15%, via a green shoe.</p>\n<p>Like other e-commerce and gaming groups, Sea has enjoyed rapid growth, with the Covid-19 pandemic spurring customers to live more of their lives online.</p>\n<p>Compared with the same period a year earlier, Sea’s revenue in the three months to June more than doubled to nearly $2.3 billion, while paying users for its digital-entertainment business and gross merchandise value for its e-commerce unit both leapt by more than 80% year-over-year.</p>\n<p>The business remains unprofitable however, reporting a net loss of $434 million for the quarter, or $321 million excluding share-based pay to staff. It generated cumulative annual net losses of more than $4 billion in 2018 through 2020.</p>\n<p>Sea’s shares have surged in recent years, giving it a market capitalization of roughly $185 billion. That makes it the region’s biggest listed company, according to S&amp;P Global Market Intelligence data, and has allowed it to pull ahead of some of China’s big tech companies, such asJD.comInc.andPinduoduoInc.,as the Chinese tech industry confronts a series of government crackdowns.</p>\n<p>Sea itself isone of many tech groups backedby China’s Tencent, and it publishes Tencent games such as League of Legends and Arena of Valor in the region. Tencent held a 22.9% stake as of March 5, according to Sea’s annual report.</p>\n<p>The planned issuance is the latest in a series of fundraising deals by big tech groups in Asia. In April, Meituan, one of China’s most valuable technology companies,raised roughly $10 billionby selling stock and convertible bonds. Meituan, which competes with Alibaba and others, said it would spend some of the proceeds on researching and developing autonomous delivery vehicles, drone deliveries and other technology.</p>\n<p>Southeast Asian tech is also drawingmore interest from investors, with some seeing the planned U.S. listing of Grab Holdings Inc., operator of a superapp that offers services including ride-hailing and delivery, as a watershed moment.</p>\n<p>In May, Singapore-headquartered Grab said it planned to raise about $4.5 billion in a tie-up with a special-purpose acquisition company, or SPAC, and go public in the U.S. at a valuation of nearly $40 billion. Grab expects the deal to close in the fourth quarter.</p>\n<p>Units ofGoldman Sachs GroupInc.,JPMorgan Chase &amp; Co. andBank of AmericaCorp.are handling Sea’s offerings.</p>\n<p>Sea fell over 7% in early trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1579594bcdff311d196e8c7d1b43d16e\" tg-width=\"1156\" tg-height=\"571\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tencent-Backed Tech Giant Sea Taps Investors for About $6 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTencent-Backed Tech Giant Sea Taps Investors for About $6 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/tencent-backed-tech-giant-sea-taps-investors-for-about-6-billion-11631170423?mod=tech_lead_pos2><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 9, 2021 at 09:44 a.m. ET)\n\nSea says some of the proceeds would help expand its business, while funds could also be deployed on investments and acquisitions.\n\nSoutheast Asia’s most ...</p>\n\n<a href=\"https://www.wsj.com/articles/tencent-backed-tech-giant-sea-taps-investors-for-about-6-billion-11631170423?mod=tech_lead_pos2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"source_url":"https://www.wsj.com/articles/tencent-backed-tech-giant-sea-taps-investors-for-about-6-billion-11631170423?mod=tech_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109486521","content_text":"(Update: Sept 9, 2021 at 09:44 a.m. ET)\n\nSea says some of the proceeds would help expand its business, while funds could also be deployed on investments and acquisitions.\n\nSoutheast Asia’s most valuable listed company, Sea Ltd., plans to raise about $6 billion or more in new funds, capitalizing on investor enthusiasm for the region’s fast-growing technology industry.\nTheTencent HoldingsLtd.TCEHY-2.95%-backed gaming, e-commerce and digital-finance company said in a filing late Wednesday that it would raise the capital by selling new shares and convertible bonds. Sea said some of the proceeds would help expand its business, while funds could also be deployed on “potential strategic investments and acquisitions.”\nThe company says its Shopee unit, which competes with rivals including Alibaba Group Holding Ltd.’s Lazada unit, is the largest e-commerce platform in Southeast Asia and Taiwan.\nSea, which is listed on the New York Stock Exchange, plans to sell 11 million American depositary shares and $2.5 billion of five-year convertible bonds.\n\nBased on Wednesday’s closing price for Sea shares, of $343.80, the stock sale would be worth close to $3.8 billion, although deals like this are typically sold at a discount to the market price. Sea and its banks expect the final price to be set Thursday, according to a term sheet seen by The Wall Street Journal. The deal’s underwriters have the option to increase the size of both offerings by 15%, via a green shoe.\nLike other e-commerce and gaming groups, Sea has enjoyed rapid growth, with the Covid-19 pandemic spurring customers to live more of their lives online.\nCompared with the same period a year earlier, Sea’s revenue in the three months to June more than doubled to nearly $2.3 billion, while paying users for its digital-entertainment business and gross merchandise value for its e-commerce unit both leapt by more than 80% year-over-year.\nThe business remains unprofitable however, reporting a net loss of $434 million for the quarter, or $321 million excluding share-based pay to staff. It generated cumulative annual net losses of more than $4 billion in 2018 through 2020.\nSea’s shares have surged in recent years, giving it a market capitalization of roughly $185 billion. That makes it the region’s biggest listed company, according to S&P Global Market Intelligence data, and has allowed it to pull ahead of some of China’s big tech companies, such asJD.comInc.andPinduoduoInc.,as the Chinese tech industry confronts a series of government crackdowns.\nSea itself isone of many tech groups backedby China’s Tencent, and it publishes Tencent games such as League of Legends and Arena of Valor in the region. Tencent held a 22.9% stake as of March 5, according to Sea’s annual report.\nThe planned issuance is the latest in a series of fundraising deals by big tech groups in Asia. In April, Meituan, one of China’s most valuable technology companies,raised roughly $10 billionby selling stock and convertible bonds. Meituan, which competes with Alibaba and others, said it would spend some of the proceeds on researching and developing autonomous delivery vehicles, drone deliveries and other technology.\nSoutheast Asian tech is also drawingmore interest from investors, with some seeing the planned U.S. listing of Grab Holdings Inc., operator of a superapp that offers services including ride-hailing and delivery, as a watershed moment.\nIn May, Singapore-headquartered Grab said it planned to raise about $4.5 billion in a tie-up with a special-purpose acquisition company, or SPAC, and go public in the U.S. at a valuation of nearly $40 billion. Grab expects the deal to close in the fourth quarter.\nUnits ofGoldman Sachs GroupInc.,JPMorgan Chase & Co. andBank of AmericaCorp.are handling Sea’s offerings.\nSea fell over 7% in early trading.","news_type":1,"symbols_score_info":{"SE":0.9}},"isVote":1,"tweetType":1,"viewCount":329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":836602761,"gmtCreate":1629473057753,"gmtModify":1631886507601,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"when sundial rises????","listText":"when sundial rises????","text":"when sundial rises????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/836602761","repostId":"2160710591","repostType":4,"repost":{"id":"2160710591","kind":"highlight","pubTimestamp":1629470661,"share":"https://ttm.financial/m/news/2160710591?lang=&edition=full","pubTime":"2021-08-20 22:44","market":"us","language":"en","title":"2 No-Brainer Stocks to Buy in the Cannabis Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2160710591","media":"Motley Fool","summary":"A multi-state operator and an unconventional pot stock are both hot buys after reporting second-quarter earnings.","content":"<p>With state cannabis legalization ramping up across the U.S. and chances of federal legalization improving, investors might not want to lose out on this evolving sector. And outstanding second-quarter earnings from these two pot stocks in particular are excellent examples of the sector's high growth and exciting upside.</p>\n<p>Florida-based&nbsp;<b><a href=\"https://laohu8.com/S/TCNNF\">Trulieve Cannabis Corporation</a> </b>(OTC:&nbsp;TCNNF)<b>&nbsp;</b>reported another great quarter with outstanding revenue growth and positive earnings before interest, tax, depreciation, and amortization (EBITDA). Meanwhile, marijuana REIT<b> <a href=\"https://laohu8.com/S/IIPR\">Innovative Industrial Properties Inc</a> </b>(NYSE:&nbsp;IIPR) not only grew revenue, but also profits. Both are profitable companies expanding at a rapid rate to capture the cannabis market in the U.S. Let's dig into their second-quarter results and determine why they could be the best fit for your portfolio.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F639496%2Fpiggy-bank.jpeg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty&nbsp;Images.</p>\n<h2>Trulieve Cannabis' Q2 turned out even better than Q1</h2>\n<p>The credit for Trulieve's consistent performance mostly goes to its dominance in its home state, where it operates 85 stores. Its total revenue grew 78% year over year to $215 million. Adjusted EBITDA came in at $95 million, a 55% jump from the prior-year quarter. The company also generated net profits of $41 million, a 116% year-over-year increase. Q2 marks the company's 14th consecutive quarter of profitability, which is impressive considering how its Canadian counterparts are struggling to generate profits. </p>\n<p>For the six months ended June 30, the company has reached $409 million in revenue. If it continues to grow at this rate, I wouldn't be surprised if it ends 2021 with more than $1 billion. Note that these numbers don't include the revenue generated from the <b>Harvest Health &amp; Recreation&nbsp;</b>acquisition (once it completes), so expect them to climb even higher. Trulieve's purchase of Arizona-based Harvest Health in May pushed its store count to a total of 140, and it now boasts 3 million square feet of cultivation capacity in the U.S. The move also gives Trulieve access to markets in Arizona (which recently legalized recreational cannabis), Pennsylvania, and Maryland.</p>\n<p>Initially, investors were concerned with Trulieve's focus only on the Florida market; I was too. But a smart company knows to strengthen its roots first and then focus on expanding, and I applaud Trulieve for doing just that. The company used its capital resources well and continued generating profits first, without going on an acquisition spree. This made room for the Harvest acquisition to bolster Trulieve's presence in key cannabis markets across the nation. The company had cash and cash equivalents of $289 million and net debt of $118 million at the end of Q2. </p>\n<p>The only concern I have is that most of its revenue generated during the quarter came from the sale of medical cannabis products (all that's currently legal in Florida). Trulieve will need to add focus on recreational revenue going forward. Markets in <a href=\"https://laohu8.com/S/NWY\">New York</a>, Arizona, and New Jersey (which recently legalized recreational marijuana) present a tremendous opportunity for U.S. cannabis companies, but Trulieve has no stores in any of these states yet. </p>\n<p>Analysts expect a 132% upside for Trulieve's stock in the next 12 months, which I think is possible looking at the rate the company is growing. </p>\n<h2>This REIT's stock popped after another strong quarter</h2>\n<p>Innovative Industrial Properties is not directly linked to cannabis, but management has taken good advantage of the marijuana boom in the U.S. Its business model, in which it acquires properties from medical cannabis companies and leases them back to the sellers, has worked wonders for both parties; because cannabis is illegal at the federal level in the U.S., access to capital can be hard for marijuana companies to find in other ways. Besides allowing investors indirect access to the industry, Innovative is also a real estate investment trust (or REIT), meaning it is mandated by law to pay 90% of its taxable income as dividends.&nbsp;</p>\n<p>As expected, Innovative's second quarter showed another great performance, and its stock is up 10% since those results were released Aug. 5. In the quarter ended June 30, total revenue jumped 101% year over year to $49 million. (The company's main source of income is rental income paid by the cannabis companies.) Rising revenue also brought in another quarter of profits. Net income grew to $29 million from $13 million in the year-ago period, and adjusted funds from operations, or AFFO, surged by 105% to $43 million for the quarter. </p>\n<p>For a REIT, AFFO plays the same role as net earnings do for a non-REIT, showing how much cash is available to be paid to shareholders as dividends. Rising AFFO is a good sign, meaning a business (in this case, Innovative) is capable of consistently paying dividends. The company paid a quarterly dividend of $1.40 per share on July 15, which was an increase of 6% from the first quarter and a 32% hike from the year-ago period. It marked the 11th dividend increase since its initial public offering in 2016. </p>\n<p>Currently, the company owns 73 properties in 18 states totaling 6.8 million square feet of space; 100% of its properties are leased out by cannabis companies. Between April 1 and Aug. 4, the company made five acquisitions of new properties and three lease amendments for existing properties.&nbsp;Some of its tenants include popular cannabis players <b>Cresco Labs, Trulieve Cannabis</b>,&nbsp;<b>Curaleaf Holdings</b>, and&nbsp;<b><a href=\"https://laohu8.com/S/GNBC\">Green</a> Thumb Industries</b>. These companies' expansion plans, and ever-expanding state legalization, lead me to believe Innovative will continue to grow.&nbsp;</p>\n<p>If you want to create wealth by investing, you need to keep a long time frame in mind. Growth stocks need time to show their full potential, especially in a nascent industry like marijuana. Both Trulieve and Innovative have strong financials and can flourish as the industry expands. Risk-averse investors can start with a small investment in these high-growth pot stocks that have the potential to double their money five to 10 years down the line.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 No-Brainer Stocks to Buy in the Cannabis Sector</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 No-Brainer Stocks to Buy in the Cannabis Sector\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/20/2-no-brainer-stocks-to-buy-in-cannabis-sector/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With state cannabis legalization ramping up across the U.S. and chances of federal legalization improving, investors might not want to lose out on this evolving sector. And outstanding second-quarter ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/20/2-no-brainer-stocks-to-buy-in-cannabis-sector/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IIPR":"Innovative Industrial Properties Inc","TCNNF":"Trulieve Cannabis Corporation"},"source_url":"https://www.fool.com/investing/2021/08/20/2-no-brainer-stocks-to-buy-in-cannabis-sector/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160710591","content_text":"With state cannabis legalization ramping up across the U.S. and chances of federal legalization improving, investors might not want to lose out on this evolving sector. And outstanding second-quarter earnings from these two pot stocks in particular are excellent examples of the sector's high growth and exciting upside.\nFlorida-based Trulieve Cannabis Corporation (OTC: TCNNF) reported another great quarter with outstanding revenue growth and positive earnings before interest, tax, depreciation, and amortization (EBITDA). Meanwhile, marijuana REIT Innovative Industrial Properties Inc (NYSE: IIPR) not only grew revenue, but also profits. Both are profitable companies expanding at a rapid rate to capture the cannabis market in the U.S. Let's dig into their second-quarter results and determine why they could be the best fit for your portfolio.\n\nImage source: Getty Images.\nTrulieve Cannabis' Q2 turned out even better than Q1\nThe credit for Trulieve's consistent performance mostly goes to its dominance in its home state, where it operates 85 stores. Its total revenue grew 78% year over year to $215 million. Adjusted EBITDA came in at $95 million, a 55% jump from the prior-year quarter. The company also generated net profits of $41 million, a 116% year-over-year increase. Q2 marks the company's 14th consecutive quarter of profitability, which is impressive considering how its Canadian counterparts are struggling to generate profits. \nFor the six months ended June 30, the company has reached $409 million in revenue. If it continues to grow at this rate, I wouldn't be surprised if it ends 2021 with more than $1 billion. Note that these numbers don't include the revenue generated from the Harvest Health & Recreation acquisition (once it completes), so expect them to climb even higher. Trulieve's purchase of Arizona-based Harvest Health in May pushed its store count to a total of 140, and it now boasts 3 million square feet of cultivation capacity in the U.S. The move also gives Trulieve access to markets in Arizona (which recently legalized recreational cannabis), Pennsylvania, and Maryland.\nInitially, investors were concerned with Trulieve's focus only on the Florida market; I was too. But a smart company knows to strengthen its roots first and then focus on expanding, and I applaud Trulieve for doing just that. The company used its capital resources well and continued generating profits first, without going on an acquisition spree. This made room for the Harvest acquisition to bolster Trulieve's presence in key cannabis markets across the nation. The company had cash and cash equivalents of $289 million and net debt of $118 million at the end of Q2. \nThe only concern I have is that most of its revenue generated during the quarter came from the sale of medical cannabis products (all that's currently legal in Florida). Trulieve will need to add focus on recreational revenue going forward. Markets in New York, Arizona, and New Jersey (which recently legalized recreational marijuana) present a tremendous opportunity for U.S. cannabis companies, but Trulieve has no stores in any of these states yet. \nAnalysts expect a 132% upside for Trulieve's stock in the next 12 months, which I think is possible looking at the rate the company is growing. \nThis REIT's stock popped after another strong quarter\nInnovative Industrial Properties is not directly linked to cannabis, but management has taken good advantage of the marijuana boom in the U.S. Its business model, in which it acquires properties from medical cannabis companies and leases them back to the sellers, has worked wonders for both parties; because cannabis is illegal at the federal level in the U.S., access to capital can be hard for marijuana companies to find in other ways. Besides allowing investors indirect access to the industry, Innovative is also a real estate investment trust (or REIT), meaning it is mandated by law to pay 90% of its taxable income as dividends. \nAs expected, Innovative's second quarter showed another great performance, and its stock is up 10% since those results were released Aug. 5. In the quarter ended June 30, total revenue jumped 101% year over year to $49 million. (The company's main source of income is rental income paid by the cannabis companies.) Rising revenue also brought in another quarter of profits. Net income grew to $29 million from $13 million in the year-ago period, and adjusted funds from operations, or AFFO, surged by 105% to $43 million for the quarter. \nFor a REIT, AFFO plays the same role as net earnings do for a non-REIT, showing how much cash is available to be paid to shareholders as dividends. Rising AFFO is a good sign, meaning a business (in this case, Innovative) is capable of consistently paying dividends. The company paid a quarterly dividend of $1.40 per share on July 15, which was an increase of 6% from the first quarter and a 32% hike from the year-ago period. It marked the 11th dividend increase since its initial public offering in 2016. \nCurrently, the company owns 73 properties in 18 states totaling 6.8 million square feet of space; 100% of its properties are leased out by cannabis companies. Between April 1 and Aug. 4, the company made five acquisitions of new properties and three lease amendments for existing properties. Some of its tenants include popular cannabis players Cresco Labs, Trulieve Cannabis, Curaleaf Holdings, and Green Thumb Industries. These companies' expansion plans, and ever-expanding state legalization, lead me to believe Innovative will continue to grow. \nIf you want to create wealth by investing, you need to keep a long time frame in mind. Growth stocks need time to show their full potential, especially in a nascent industry like marijuana. Both Trulieve and Innovative have strong financials and can flourish as the industry expands. Risk-averse investors can start with a small investment in these high-growth pot stocks that have the potential to double their money five to 10 years down the line.","news_type":1,"symbols_score_info":{"IIPR":0.9,"TCNNF":0.9}},"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":827862889,"gmtCreate":1634444122203,"gmtModify":1634444122656,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"sea tsunami up up up ....like like","listText":"sea tsunami up up up ....like like","text":"sea tsunami up up up ....like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/827862889","repostId":"2175112192","repostType":4,"repost":{"id":"2175112192","kind":"highlight","pubTimestamp":1634312035,"share":"https://ttm.financial/m/news/2175112192?lang=&edition=full","pubTime":"2021-10-15 23:33","market":"us","language":"en","title":"5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2175112192","media":"Motley Fool","summary":"These well-known and widely held companies should deliver jaw-dropping revenue growth over the next five years.","content":"<p>Since the Great Recession ended more than 12 years ago, growth stocks have ruled the roost on Wall Street. A combination of historically low lending rates and ongoing quantitative easing measures from the Federal Reserve have rolled out the red carpet for fast-paced companies and given them access to abundant cheap capital.</p>\n<p>Yet for some high-growth stocks, their parabolic sales increases are just beginning. Based on analysts' consensus sales estimates, the following five big-name stocks are expected to increase their sales by 356% to as much as 1,605% by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Ffinancial-newspaper-graph-showing-gains-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Shopify: 464% implied sales growth by 2025</h2>\n<p>The first well-known hypergrowth stock that could deliver a jaw-dropping sales increase over the next five years is cloud-based e-commerce platform <b>Shopify</b> (NYSE:SHOP). Following $2.93 billion in full-year sales in 2020, Wall Street is forecasting $16.54 billion in annual sales by mid-decade. That's a 464% increase, for those of you keeping score at home.</p>\n<p>The beauty of the Shopify operating model is that it finds itself in the right place at the right time. Prior to 2020, businesses were shifting their presence online at a steady pace. But in the wake of the pandemic, businesses of all sizes have come to realize how important it is to have their products available for sale on e-commerce marketplaces. Known best for helping small merchants reach large audiences, Shopify estimates its total addressable market for small businesses is currently $153 billion. Thus, with $2.9 billion in sales last year and the company constantly innovating and introducing new tools, it's just scratching the tip of the iceberg in terms of its potential.</p>\n<p>What's more, Shopify is benefiting from its high-margin subscription-based services. Whereas entrepreneurs can take advantage of the company's basic services for $29 a month, it offers its core service to small businesses for $79/mo. to $299/mo., or its Shopify Plus service for $2,000/mo. to larger businesses. This is a company that shouldn't have any issue growing its operating margins over time.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Ftelemedicine-patient-doctor-physician-virtual-conference-healthcare-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teladoc Health: 356% implied sales growth by 2025</h2>\n<p>Another big-name stock on track to produce eye-popping sales growth over the next half-decade is telemedicine kingpin <b>Teladoc Health</b> (NYSE:TDOC). Last year, Teladoc generated $1.09 billion in sales. But by 2025, Wall Street's consensus has the company pegged for $4.98 billion in sales.</p>\n<p>There's little question that Teladoc Health benefited immensely from the COVID-19 pandemic. With physicians wanting to keep potentially sick and high-risk people out of their offices, demand for virtual visits soared.</p>\n<p>But this isn't a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-trick pony. What Teladoc is doing is fundamentally altering the personalized treatment landscape. While virtual services won't replace all in-person visits, it's far more convenient for patients, and it can help doctors keep better tabs on chronically ill patients. Ultimately, that's a recipe for improved patient outcomes and less money out of the pockets of health insurers.</p>\n<p>Teladoc also expects a serious long-term growth boost from the acquisition of leading applied health signals company Livongo Health. Livongo leans on artificial intelligence to send tips to its chronic care members to help them lead healthier lives. With a focus on diabetes, hypertension, and weight management, Livongo's services could cater to a large swath of the U.S. adult population.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Fretail-shopping-store-online-sale-smartphone-website-ecommerce-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sea Limited: 430% implied sales growth by 2024</h2>\n<p>Singapore-based <b>Sea Limited</b> (NYSE:SE) is expected to deliver such robust sales growth that it doesn't even need a full five years. With consensus estimates looking out to 2024, the company's sales are projected to more than quintuple to $23.2 billion from $4.38 billion in 2020.</p>\n<p>Sea's success is the result of three very different but rapidly growing segments. The first, digital entertainment, is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea had approximately 725 million quarterly active mobile game users in the June-ended quarter, 12.7% of which were paying customers.&nbsp; For some context, only about 2% of mobile gamers are being converted to paying customers industrywide.</p>\n<p>Second, and arguably the more intriguing segment, is its e-commerce platform Shopee. Shopee has consistently been the most downloaded shopping app in Southeastern Asia, and it managed $15 billion in gross merchandise value (GMV) on its platform in the second quarter. This $60 billion annual run-rate is a 500% increase from what it did in all of 2018 ($10 billion in GMV). E-commerce sales in the emerging market countries Shopee serves are still in the early stages of ramping up.</p>\n<p>Third, Sea's digital financial services segment has almost 33 million paying digital wallet customers. Since many of the markets Sea serves are underbanked, mobile wallets could be a key growth driver for the company.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Fsiblings-watch-tv-family-entertainment-show-network-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Roku: 408% implied sales growth by 2025</h2>\n<p>Television streaming platform <b>Roku</b> (NASDAQ:ROKU) is yet another big-name stock on pace to more than quintuple sales in just five years. After bringing in $1.78 billion in full-year sales in 2020, Wall Street's consensus is calling for about $9.05 billion in revenue by 2025. That's an increase of 408%.</p>\n<p>Roku has two key catalysts in its sails. First, there's ongoing cord-cutting from consumers. Over a four-year stretch, the number of U.S. households with traditional cable, satellite, or telcoTV services has fallen by more than 21 million to 75.6 million, according to a report from NScreenMedia.com. Meanwhile, the number of households without these traditional services now stands at more than 50 million. The opportunity to provide these households with streaming content of their choosing, be it free or paid content, is clearly helping Roku win over customers (55.1 million active accounts, as of June 2021).</p>\n<p>But the more exciting opportunity for Roku is with programmatic digital ads. As consumers shift their viewing content from traditional cable and satellite to streaming providers, advertisers are responding by putting more of their budget to work with companies like Roku. More active accounts will give Roku increased ad pricing power, which in turn will it allow it grow its average revenue per user (ARPU) at a rapid clip. In the June-ended quarter, ARPU grew by 46%, even though active accounts increased by only 28% year over year.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Fcoronavirus-vaccine-doctor-patient-healthcare-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna: 1,605% implied sales growth by 2025</h2>\n<p>However, the king of the mountain, at least on this list, is biotech stock <b>Moderna</b> (NASDAQ:MRNA). Sales for Moderna are expected to grow from a reported $803.4 million in 2020 to an estimated $13.7 billion by 2025. That's an increase of more than 1,600%!</p>\n<p>While it's not uncommon to see rapid nominal sales growth when clinical-stage biotech stocks introduce their first drug for sale, Moderna's launch from minimal revenue to multiple billions occurred quickly, thanks to its development of a COVID-19 vaccine, mRNA-1273. In clinical studies, mRNA-1273 led to a 94% vaccine efficacy and demonstrably helped inoculated patients stay out of the hospital with severe forms of the illness.</p>\n<p>From a business standpoint, Moderna continues to benefit from the need to inoculate billions of people worldwide, as well as the mutability of the SARS-CoV-2 virus that causes COVID-19. The need for booster shots or annual vaccines could give Moderna a source of recurring revenue.</p>\n<p>On the other hand, the vaccine space is growing more crowded, with a number of new entrants expected within the U.S. and globally. Considering that mRNA-1273 is the company's only revenue-generating drug, Moderna's $126 billion market cap can best be described as precarious.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 23:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/15/5-big-name-stocks-increase-sales-356-to-1605/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since the Great Recession ended more than 12 years ago, growth stocks have ruled the roost on Wall Street. A combination of historically low lending rates and ongoing quantitative easing measures from...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/15/5-big-name-stocks-increase-sales-356-to-1605/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","SHOP":"Shopify Inc","TDOC":"Teladoc Health Inc.","SE":"Sea Ltd","ROKU":"Roku Inc"},"source_url":"https://www.fool.com/investing/2021/10/15/5-big-name-stocks-increase-sales-356-to-1605/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175112192","content_text":"Since the Great Recession ended more than 12 years ago, growth stocks have ruled the roost on Wall Street. A combination of historically low lending rates and ongoing quantitative easing measures from the Federal Reserve have rolled out the red carpet for fast-paced companies and given them access to abundant cheap capital.\nYet for some high-growth stocks, their parabolic sales increases are just beginning. Based on analysts' consensus sales estimates, the following five big-name stocks are expected to increase their sales by 356% to as much as 1,605% by 2025.\nImage source: Getty Images.\nShopify: 464% implied sales growth by 2025\nThe first well-known hypergrowth stock that could deliver a jaw-dropping sales increase over the next five years is cloud-based e-commerce platform Shopify (NYSE:SHOP). Following $2.93 billion in full-year sales in 2020, Wall Street is forecasting $16.54 billion in annual sales by mid-decade. That's a 464% increase, for those of you keeping score at home.\nThe beauty of the Shopify operating model is that it finds itself in the right place at the right time. Prior to 2020, businesses were shifting their presence online at a steady pace. But in the wake of the pandemic, businesses of all sizes have come to realize how important it is to have their products available for sale on e-commerce marketplaces. Known best for helping small merchants reach large audiences, Shopify estimates its total addressable market for small businesses is currently $153 billion. Thus, with $2.9 billion in sales last year and the company constantly innovating and introducing new tools, it's just scratching the tip of the iceberg in terms of its potential.\nWhat's more, Shopify is benefiting from its high-margin subscription-based services. Whereas entrepreneurs can take advantage of the company's basic services for $29 a month, it offers its core service to small businesses for $79/mo. to $299/mo., or its Shopify Plus service for $2,000/mo. to larger businesses. This is a company that shouldn't have any issue growing its operating margins over time.\nImage source: Getty Images.\nTeladoc Health: 356% implied sales growth by 2025\nAnother big-name stock on track to produce eye-popping sales growth over the next half-decade is telemedicine kingpin Teladoc Health (NYSE:TDOC). Last year, Teladoc generated $1.09 billion in sales. But by 2025, Wall Street's consensus has the company pegged for $4.98 billion in sales.\nThere's little question that Teladoc Health benefited immensely from the COVID-19 pandemic. With physicians wanting to keep potentially sick and high-risk people out of their offices, demand for virtual visits soared.\nBut this isn't a one-trick pony. What Teladoc is doing is fundamentally altering the personalized treatment landscape. While virtual services won't replace all in-person visits, it's far more convenient for patients, and it can help doctors keep better tabs on chronically ill patients. Ultimately, that's a recipe for improved patient outcomes and less money out of the pockets of health insurers.\nTeladoc also expects a serious long-term growth boost from the acquisition of leading applied health signals company Livongo Health. Livongo leans on artificial intelligence to send tips to its chronic care members to help them lead healthier lives. With a focus on diabetes, hypertension, and weight management, Livongo's services could cater to a large swath of the U.S. adult population.\nImage source: Getty Images.\nSea Limited: 430% implied sales growth by 2024\nSingapore-based Sea Limited (NYSE:SE) is expected to deliver such robust sales growth that it doesn't even need a full five years. With consensus estimates looking out to 2024, the company's sales are projected to more than quintuple to $23.2 billion from $4.38 billion in 2020.\nSea's success is the result of three very different but rapidly growing segments. The first, digital entertainment, is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea had approximately 725 million quarterly active mobile game users in the June-ended quarter, 12.7% of which were paying customers.  For some context, only about 2% of mobile gamers are being converted to paying customers industrywide.\nSecond, and arguably the more intriguing segment, is its e-commerce platform Shopee. Shopee has consistently been the most downloaded shopping app in Southeastern Asia, and it managed $15 billion in gross merchandise value (GMV) on its platform in the second quarter. This $60 billion annual run-rate is a 500% increase from what it did in all of 2018 ($10 billion in GMV). E-commerce sales in the emerging market countries Shopee serves are still in the early stages of ramping up.\nThird, Sea's digital financial services segment has almost 33 million paying digital wallet customers. Since many of the markets Sea serves are underbanked, mobile wallets could be a key growth driver for the company.\nImage source: Getty Images.\nRoku: 408% implied sales growth by 2025\nTelevision streaming platform Roku (NASDAQ:ROKU) is yet another big-name stock on pace to more than quintuple sales in just five years. After bringing in $1.78 billion in full-year sales in 2020, Wall Street's consensus is calling for about $9.05 billion in revenue by 2025. That's an increase of 408%.\nRoku has two key catalysts in its sails. First, there's ongoing cord-cutting from consumers. Over a four-year stretch, the number of U.S. households with traditional cable, satellite, or telcoTV services has fallen by more than 21 million to 75.6 million, according to a report from NScreenMedia.com. Meanwhile, the number of households without these traditional services now stands at more than 50 million. The opportunity to provide these households with streaming content of their choosing, be it free or paid content, is clearly helping Roku win over customers (55.1 million active accounts, as of June 2021).\nBut the more exciting opportunity for Roku is with programmatic digital ads. As consumers shift their viewing content from traditional cable and satellite to streaming providers, advertisers are responding by putting more of their budget to work with companies like Roku. More active accounts will give Roku increased ad pricing power, which in turn will it allow it grow its average revenue per user (ARPU) at a rapid clip. In the June-ended quarter, ARPU grew by 46%, even though active accounts increased by only 28% year over year.\nImage source: Getty Images.\nModerna: 1,605% implied sales growth by 2025\nHowever, the king of the mountain, at least on this list, is biotech stock Moderna (NASDAQ:MRNA). Sales for Moderna are expected to grow from a reported $803.4 million in 2020 to an estimated $13.7 billion by 2025. That's an increase of more than 1,600%!\nWhile it's not uncommon to see rapid nominal sales growth when clinical-stage biotech stocks introduce their first drug for sale, Moderna's launch from minimal revenue to multiple billions occurred quickly, thanks to its development of a COVID-19 vaccine, mRNA-1273. In clinical studies, mRNA-1273 led to a 94% vaccine efficacy and demonstrably helped inoculated patients stay out of the hospital with severe forms of the illness.\nFrom a business standpoint, Moderna continues to benefit from the need to inoculate billions of people worldwide, as well as the mutability of the SARS-CoV-2 virus that causes COVID-19. The need for booster shots or annual vaccines could give Moderna a source of recurring revenue.\nOn the other hand, the vaccine space is growing more crowded, with a number of new entrants expected within the U.S. and globally. Considering that mRNA-1273 is the company's only revenue-generating drug, Moderna's $126 billion market cap can best be described as precarious.","news_type":1,"symbols_score_info":{"MRNA":0.9,"ROKU":0.9,"SE":0.9,"SHOP":0.9,"TDOC":0.9}},"isVote":1,"tweetType":1,"viewCount":499,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609255210,"gmtCreate":1638287916044,"gmtModify":1638287916186,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Apple rise a day keep the shorters away...i wish..like like","listText":"Apple rise a day keep the shorters away...i wish..like like","text":"Apple rise a day keep the shorters away...i wish..like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609255210","repostId":"1158390889","repostType":4,"isVote":1,"tweetType":1,"viewCount":3021,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":869722194,"gmtCreate":1632323283218,"gmtModify":1632801213729,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Fed is always the news feeder who always fed on what&nbsp;it want to feed on,right?[财迷]&nbsp;","listText":"Fed is always the news feeder who always fed on what&nbsp;it want to feed on,right?[财迷]&nbsp;","text":"Fed is always the news feeder who always fed on what it want to feed on,right?[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/869722194","repostId":"2169654193","repostType":4,"isVote":1,"tweetType":1,"viewCount":768,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}